Top

William G. Wierda, M.D., Ph.D.

Department of Leukemia, Division of Cancer Medicine

About Dr. Wierda

CLL is a unique disease in which to do translational research because of the circulating tumor cells that can be sampled before, during and after treatment; providing the exceptional opportunity to study and confirm in vivomechanisms of drug action and for hypothesis testing. MD Anderson Cancer Center (MDACC) is a uniquely established clinical Institution in which to perform translational research. Over three-fourths of patients with CLL are enrolled on clinical trial and provide tissue samples before, during, and after treatment for correlative studies. Most of the drugs currently approved for CLL have been developed and/or investigated at MDACC, including fludarabine, alemtuzumab, ofatumumab, and rituximab.

Dr. Wierda is uniquely qualified to be the Principal Investigator (PI) for this grant owing clinical and translational research and expertise in CLL. In 2001, Dr. Wierda moved to Houston as an Assistant Professor of Medicine in the Department of Leukemia at MDACC. He was promoted to Associate Professor of Medicine in 2007. In 2012, he was promoted to Professor of Medicine and continue clinical and translational research in CLL. Dr. Wierda’s outpatient clinical activities are more than 90% dedicated to seeing and treating patients with CLL. At MDACC, Dr. Wierda has been PI, Co-PI, or collaborator on numerous clinical trials and conduct translational research in CLL. He has published many peer-reviewed articles on various clinical and translational aspects of CLL and drug development and have given numerous lectures on treatments for patients with CLL. Dr. Wierda’s particular research interests in CLL are prognostic factors and developing prognostic models in CLL, immune and gene therapies for patients with CLL, developing chemoimmunotherapy regimens and treatment strategies for relapsed and refractory patients with CLL.

Meet William Wierda, M.D., Ph.D.

In the News

A typical B cell and an affected B cell from Richter transformation.

Richter transformation: What chronic lymphocytic leukemia (CLL) patients should know

Leukemia specialist William Wierda, M.D., Ph.D.

Leukemia specialist: Identifying new treatments is the most gratifying part of my job

Patient care

Present Title & Affiliation

Primary Appointment

Endowed Distinguished Professor Jane and John Justin Distinguished Chair in Leukemia Research in Honor of Dr. Elihu Estey, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Deputy Department Chair, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

Executive Medical Director, Inpatient Medical Services, The University of Texas MD Anderson Cancer Center, Houston, TX

Professor of Medicine, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

Section Chief - Chronic Lymphocytic Leukemia, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

Center Medical Director, Department of Leukemia Center, The University of Texas M. D. Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Jane and John Justin Distinguished Chair in Leukemia Research in Honor of Dr. Elihu Estey, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

Professor of Medicine, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

Research Interests

Dr. Wierda's research is in Chronic Lymphocytic Leukemia (CLL) prognostic factors and developing prognostic models in CLL, immune and gene therapies for patients with CLL, and developing chemoimmunotherapy regimens and treatment strategies for relapsed and refractory patients with CLL.

Clinical Interests

Dr. Wierda's clinical interest is providing Chronic Lymphocytic Leukemia (CLL) patients with the best treatment options including immune and gene therapies, chemoimmunotherapy regimens and treatment strategies for relapsed and refractory patients.

Education & Training

Degree-Granting Education

1993	University of Health Sciences/The Chicago Medical School, North Chicago, Illinois, US, MD
1992	University of Health Sciences/The Chicago Medical School, North Chicago, Illinois, US, Microbiology and Immunology, Ph.D
1986	University of California, Riverside, California, US, Biochemistry, BS

Postgraduate Training

1996-1999	Subspecialty Fellowship, Hematology and Oncology, University of California, San Diego, California
1993-1996	Internship and Residency, Internal Medicine, Duke University Medical Center, Durham, North Carolina

Experience & Service

Academic Appointments

D.B. Lane Cancer Research Distinguished Professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, 2017 - 2022

Associate Professor of Medicine, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, 2007 - 2012

Assistant Professor of Medicine, Department of Leukemia, University of Texas M.D. Anderson Cancer Center, Houston, TX, 2001 - 2007

Instructor, Department of Medicine, University of California San Diego, San Diego, CA, 1999 - 2001

Staff Physician, Department of Hematology and Oncology, San Diego Veterans Healthcare System, San Diego, CA, 1999 - 2001

Assistant Instructor of Immunology, Department of Immunology, UHS/School of Related Health Science, North Chicago, IL, 1989 - 1991

Administrative Appointments/Responsibilities

2025 iwCLL Program Planning Committee Member, iwCLL, 2024 - 2025

MDACC Incident Command, Patient Care Section Head, The University of Texas MD Anderson Cancer Center, Houston, TX, 2020 - Present

Director, MDACC COVID Unit, The University of Texas MD Anderson Cancer Center, Houston, TX, 2020 - 2022

Deputy Department Chair, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, 2019 - Present

Primary Lead, The University of Texas MD Anderson Cancer Center - CLL Moon Shot Program, Houston, TX, 2019 - Present

Executive Medical Director, Inpatient Medical Services, The University of Texas MD Anderson Cancer Center, Houston, TX, 2016 - Present

Co-Lead, The University of Texas MD Anderson Cancer Center - CLL Moon Shot Program, Houston, TX, 2014 - 2019

Section Chief - Chronic Lymphocytic Leukemia, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, 2011 - Present

Center Medical Director, Department of Leukemia Center, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 2009 - Present

Other Appointments/Responsibilities

Chair, MDACC Chapter of American Association of University Professors (AAUP), Houston, TX, 2022 - Present

President and CEO, CLL Global Research Foundation (CLLGRF), Houston, TX, 2019 - Present

Voting member, International Working Group for CLL (IWCLL), Cologne, 2019 - Present

Chair, NCCN-CLL and Hairy Cell Leukemia Panel, Houston, TX, 2017 - Present

Co-Chairman, NCCN - Non-Hodgkin's Lymphoma Panel, Houston, TX, 2009 - 2017

Organizer/Chairman - Leukemia Planning Clinic, The University of Texas MD Anderson Cancer Center, Houston, TX, 2006 - 2013

Institutional Committee Activities

Committee Member, Brown Foundation Committee, 2024 - Present

Committee Member, Inpatient Patient Experience Committee meeting, 2023 - Present

Chair, Faculty Senate Welfare Committee, 2023 - Present

Committee Member, Institutional Survey Readiness Steering Committee (ISRSC), 2022 - Present

Committee Member, Transfer Center Committee, 2020 - Present

Committee Member, HAL's Expansion Operations Committee, 2020 - Present

Committee Member, Patient Flow Action Team, 2020 - Present

Committee Member, Service Line Learning Lab Committee, 2020 - Present

Committee Member, Inpatient Planning Committee, 2020 - Present

Committee Member, ICU Utilization and Goals of Care, 2020 - Present

Lead, COVID Floor Operations, 2020 - 2022

Committee Member, CCLT Covid Core Leadership Team, 2020 - Present

Committee Member, Discharge & Readmissions Patient Flow Team, 2020 - Present

Committee Member, Discharge Huddle Action Team, 2020 - Present

Committee Member, DoCM Executive Council, 2020 - Present

Co-Lead, MDACC Leukemia Service Line, 2020 - Present

Senator, MDACC Faculty Senate, 2019 - Present

Member, Promotion and Tenure Committee, 2019 - 2022

Co-Chair, Leukemia Planning Committee, 2019 - Present

Member, Executive Committee of the Faculty Senate, 2019 - 2022

Member, Patient Survey Governance, 2018 - Present

Member, Virtual Care Committee, 2018 - Present

Member, Promotions and Tenure Committee (PTC, 2018 - 2021

Co-Chair, Inpatient Operations Steering Committee, 2014 - Present

Member, Clinical Research Advisory Committee, 2014 - Present

Member, PRS Budget and Finance Committee, 2012 - 2015

Member, Soarian Project Operational Leadership Team, 2012 - 2012

Chair, Administration and IT Subcommittee, 2011 - 2011

Member, Productivity Work Group, 2011 - 2011

Member, EMR Strategy Review Committee Strategic Vision and Goals Workgroup, 2011 - Present

Member, Ad Hoc Institutional Expense Analysis Steering Committee, 2011 - 2011

Member, ICU Subcommittee, 2010 - Present

Member, 24 Hour Medical Coverage Steering Committee, 2010 - 2015

Member, Institutional Chemotherapy Biotherapy Policy Task Force, 2010 - Present

Chair, Clinical Research Committee, 2008 - 2011

Member, Institutional Animal Care and Use Committee, 2007 - 2008

Member, Clinical Research Committee, 2006 - 2012

Senator, Faculty Senate, 2005 - 2009

Member, Clinical Ethics Committee, 2005 - 2008

Member, Psychosocial, Behavioral, and Health Services Research Committee (PBHSRC), 2003 - 2006

Honors & Awards

2022	Jane and John Justin Distinguished Chair in Leukemia Research in Honor of Dr. Elihu Estey
2019	President's Recognition of Faculty Excellence, The University of Texas MD Anderson Cancer Center
2018	2018 Faculty Achievement Award in Patient Care, MD Anderson Cancer Center
2017	D.B. Lane Cancer Research Distinguished Professor
2017	Melvin L. Samuels Award for Excellence in Patient Care, MD Anderson Division of Cancer Medicine
2011	Waun Ki Hong Award for Excellence in Team Science, Division of Cancer Medicine - UT MD Anderson Cancer Center
2009	Faculty Educator of the Month - December, The University of Texas M. D. Anderson Cancer Center
2006	Clinical Scholar Award, Leukemia & Lymphoma Society
1998	Clinical Fellowship Award, American Cancer Society
1993	Chicago Medical School Dean's Award for Service, The Chicago Medical School
1992	Nickerson Award for Excellence in Graduate Studies and Research, UHS/CMS
1991	Alpha Omega Alpha Honor Medical Society
1991	Ben Blivaiss M.D./Ph.D. Travel Award, UHS/CMS

Professional Memberships

American Association of University Professors

2022 - Present

European Research Initiative on CLL (ERIC)

2021 - Present

Society for Immunotherapy of Cancer (SITC)

2018 - Present

European Hematology Association

2014 - Present

Society of Hematologic Oncology (SOHO)

2012 - Present

National Comprehensive Cancer Network (NCCN)

2007 - Present

Southwest Oncology Group

2006 - Present

Texas Society of Medical Oncology

2004 - Present

Harris County Medical Association

2001 - Present

American Society of Clinical Oncologists

2001 - Present

Texas Medical Association

2001 - Present

American Association of Immunologists

2000 - Present

American Society of Hematology

1996 - Present

American College of Physicians

1993 - Present

Sigma Xi

1993 - Present

Alpha Omega Alpha Honor Medical Society

1991 - Present

American Medical Association

1986 - Present

Selected Publications

Peer-Reviewed Articles

Wierda WG. Highlights in chronic lymphocytic leukemia from the 66th ASH Annual Meeting and Exposition: commentary. Clin Adv Hematol Oncol 23 Suppl 1(1):3-13, 2025. e-Pub 2025. PMID: 39907565.
Wierda WG, Shah NN, Cheah CY, Lewis D, Hoffmann MS, Coombs CC, Lamanna N, Ma S, Jagadeesh D, Munir T, Wang Y, Eyre TA, Rhodes JM, McKinney M, Lech-Maranda E, Tam CS, Jurczak W, Izutsu K, Alencar AJ, Patel MR, Seymour JF, Woyach JA, Thompson PA, Abada PB, Ho C, McNeely SC, Marella N, Nguyen B, Wang C, Ruppert AS, Nair B, Liu H, Tsai DE, Roeker LE, Ghia P. Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in patients with B-cell malignancies: analysis of the Richter transformation subgroup from the multicentre, open-label, phase 1/2 BRUIN study. Lancet Haematol 11(9):e682-e692, 2024. e-Pub 2024. PMID: 39033770.
Wierda WG. The approval of lisocabtagene maraleucel in chronic lymphocytic leukemia. Clin Adv Hematol Oncol 22(6):291-293, 2024. e-Pub 2024. PMID: 39110651.
Wierda WG, Brown J, Abramson JS, Awan F, Bilgrami SF, Bociek G, Brander D, Cortese M, Cripe L, Davis RS, Eradat H, Fakhri B, Fletcher CD, Gaballa S, Hamid MS, Hill B, Kaesberg P, Kahl B, Kamdar M, Kipps TJ, Ma S, Mosse C, Nakhoda S, Parikh S, Schorr A, Schuster S, Seshadri M, Siddiqi T, Stephens DM, Thompson M, Ujjani C, Valdez R, Wagner-Johnston N, Woyach JA, Sundar H, Dwyer M. Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 22(3):175-204, 2024. e-Pub 2024. PMID: 38626800.
Siddiqi T, Maloney DG, Kenderian SS, Brander DM, Dorritie K, Soumerai J, Riedell PA, Shah NN, Nath R, Fakhri B, Stephens DM, Ma S, Feldman T, Solomon SR, Schuster SJ, Perna SK, Tuazon SA, Ou SS, Papp E, Peiser L, Chen Y, Wierda WG. Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1-2 study. Lancet 402(10402):641-654, 2023. e-Pub 2023. PMID: 37295445.
Thompson PA, Keating MJ, Ferrajoli A, Jain N, Peterson CB, Garg N, Wang SA, Jorgensen JL, Kadia TM, Bose P, Pemmaraju N, Short NJ, Wierda WG. Venetoclax consolidation in high-risk CLL treated with ibrutinib for >/=1 year achieves a high rate of undetectable MRD. Leukemia 37(7):1444-1453, 2023. e-Pub 2023. PMID: 37138019.
Jain N, Senapati J, Thakral B, Ferrajoli A, Thompson P, Burger J, Basu S, Kadia T, Daver N, Borthakur G, Konopleva M, Pemmaraju N, Parry E, Wu CJ, Khoury J, Bueso-Ramos C, Garg N, Wang X, Lopez W, Ayala A, O'Brien S, Kantarjian H, Keating M, Allison J, Sharma P, Wierda W. A phase 2 study of nivolumab combined with ibrutinib in patients with diffuse large B-cell Richter transformation of CLL. Blood Adv 7(10):1958-1966, 2023. e-Pub 2023. PMID: 36287248.
Jain N, Senapati J, Thakral B, Ferrajoli A, Thompson P, Burger J, Basu S, Kadia T, Daver N, Borthakur G, Konopleva M, Pemmaraju N, Parry E, Wu CJ, Khoury J, Bueso-Ramos C, Garg N, Wang X, Lopez W, Ayala A, O'Brien S, Kantarjian H, Keating M, Allison J, Sharma P, Wierda W. A phase 2 study of nivolumab combined with ibrutinib in patients with diffuse large B-cell Richter transformation of CLL. Blood Advances 7(10):1958-1966, 2023. e-Pub 2023.
Wierda WG, Kipps TJ, Al-Sawaf O, Chyla B, Biondo JML, Mun Y, Jiang Y, Seymour JF. Utility of measurable residual disease for predicting treatment outcomes with BCR- and BCL2-Targeted therapies in patients with CLL. Leuk Lymphoma 63(12):2765-2784, 2022. e-Pub 2022. PMID: 35983732.
Wierda WG, Pagel JM, Davids MS, Zinzani PL, Lu Y, Liu H, Shahda S, Leow CC, Tam CS, Woyach J, Eyre TA, Mato AR. CLL-116 BRUIN CLL-322: A Phase 3 Open-Label, Randomized Study of Fixed-Duration Pirtobrutinib Plus Venetoclax and Rituximab Versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (Trial in Progress). Clin Lymphoma Myeloma Leuk 22(Suppl 2):S267, 2022. e-Pub 2022. PMID: 36163870.
Thompson PA, Jiang X, Banerjee P, Basar R, Garg N, Chen K, Kaplan M, Nandivada V, Cortes AKN, Ferrajoli A, Keating MJ, Peterson CB, Andreeff M, Rezvani K, Wierda WG. A phase two study of high dose blinatumomab in Richter's syndrome. Leukemia 36(9):2228-2232, 2022. e-Pub 2022. PMID: 35941212.
Wierda WG, Brown J, Abramson JS, Awan F, Bilgrami SF, Bociek G, Brander D, Chanan-Khan AA, Coutre SE, Davis RS, Eradat H, Fletcher CD, Gaballa S, Ghobadi A, Hamid MS, Hernandez-Ilizaliturri F, Hill B, Kaesberg P, Kamdar M, Kaplan LD, Khan N, Kipps TJ, Ma S, Mato A, Mosse C, Schuster S, Siddiqi T, Stephens DM, Ujjani C, Wagner-Johnston N, Woyach JA, Ye JC, Dwyer MA, Sundar H. NCCN Guidelines(R) Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 3.2022. J Natl Compr Canc Netw 20(6):622-634, 2022. e-Pub 2022. PMID: 35714675.
Siddiqi T, Soumerai JD, Dorritie KA, Stephens DM, Riedell PA, Arnason J, Kipps TJ, Gillenwater HH, Gong L, Yang L, Ogasawara K, Thorpe J, Wierda WG. Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL. Blood 139(12):1794-1806, 2022. e-Pub 2022. PMID: 34699592.
Wierda WG, Allan JN, Siddiqi T, Kipps TJ, Opat S, Tedeschi A, Badoux XC, Kuss BJ, Jackson S, Moreno C, Jacobs R, Pagel JM, Flinn I, Pak Y, Zhou C, Szafer-Glusman E, Ninomoto J, Dean JP, James DF, Ghia P, Tam CS. Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study. J Clin Oncol 39(34):3853-3865, 2021. e-Pub 2021. PMID: 34618601.
Jain N, Thompson P, Burger J, Ferrajoli A, Takahashi K, Estrov Z, Borthakur G, Bose P, Kadia T, Pemmaraju N, Sasaki K, Konopleva M, Jabbour E, Garg N, Wang X, Kanagal-Shamanna R, Patel K, Wang W, Jorgensen J, Wang S, Lopez W, Ayala A, Plunkett W, Gandhi V, Kantarjian H, O'Brien S, Keating M, Wierda WG. Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations. Leukemia 35(12):3421-3429, 2021. e-Pub 2021. PMID: 34007049.
Tambaro FP, Singh H, Jones E, Rytting M, Mahadeo KM, Thompson P, Daver N, DiNardo C, Kadia T, Garcia-Manero G, Chan T, Shah RR, Wierda WG. Autologous CD33-CAR-T cells for treatment of relapsed/refractory acute myelogenous leukemia. Leukemia 35(11):3282-3286, 2021. e-Pub 2021. PMID: 33833386.
Jain N, Keating M, Thompson P, Ferrajoli A, Burger JA, Borthakur G, Takahashi K, Estrov Z, Sasaki K, Fowler N, Kadia T, Konopleva M, Alvarado Y, Yilmaz M, DiNardo C, Bose P, Ohanian M, Pemmaraju N, Jabbour E, Kanagal-Shamanna R, Patel K, Wang W, Jorgensen J, Wang SA, Garg N, Wang X, Wei C, Cruz N, Ayala A, Plunkett W, Kantarjian H, Gandhi V, Wierda WG. Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia: A Nonrandomized Phase 2 Trial. JAMA Oncol 7(8):1213-1219, 2021. e-Pub 2021. PMID: 34110383.
Shah BD, Bishop MR, Oluwole OO, Logan AC, Baer MR, Donnellan WB, O'Dwyer KM, Holmes H, Arellano ML, Ghobadi A, Pagel JM, Lin Y, Cassaday RD, Park JH, Abedi M, Castro JE, DeAngelo DJ, Malone AK, Mawad R, Schiller GJ, Rossi JM, Bot A, Shen T, Goyal L, Jain RK, Vezan R, Wierda WG. KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results. Blood 138(1):11-22, 2021. e-Pub 2021. PMID: 33827116.
Byrd JC, Woyach JA, Furman RR, Martin P, O'Brien S, Brown JR, Stephens DM, Barrientos JC, Devereux S, Hillmen P, Pagel JM, Hamdy A, Izumi R, Patel P, Wang MH, Jain N, Wierda WG. Acalabrutinib in treatment-naive chronic lymphocytic leukemia. Blood 137(24):3327-3338, 2021. e-Pub 2021. PMID: 33786588.
Gopalakrishnan S, Wierda W, Chyla B, Menon R, Miles D, Humerickhouse R, Awni W, Salem AH, Mensing S, Freise KJ. Integrated Mechanistic Model of Minimal Residual Disease Kinetics With Venetoclax Therapy in Chronic Lymphocytic Leukemia. Clin Pharmacol Ther 109(2):424-432, 2021. e-Pub 2021. PMID: 32749675.
O'Brien SM, Brown JR, Byrd JC, Furman RR, Ghia P, Sharman JP, Wierda WG. Monitoring and Managing BTK Inhibitor Treatment-Related Adverse Events in Clinical Practice. Front Oncol 11:720704, 2021. e-Pub 2021. PMID: 34858810.
Byrd JC, Wierda WG, Schuh A, Devereux S, Chaves JM, Brown JR, Hillmen P, Martin P, Awan FT, Stephens DM, Ghia P, Barrientos J, Pagel JM, Woyach JA, Burke K, Covey T, Gulrajani M, Hamdy A, Izumi R, Frigault MM, Patel P, Rothbaum W, Wang MH, O'Brien S, Furman RR. Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results. Blood 135(15):1204-1213, 2020. e-Pub 2020. PMID: 31876911.
Wierda WG, Byrd JC, Abramson JS, Bilgrami SF, Bociek G, Brander D, Brown J, Chanan-Khan AA, Chavez JC, Coutre SE, Davis RS, Fletcher CD, Hill B, Kahl BS, Kamdar M, Kaplan LD, Khan N, Kipps TJ, Lim MS, Ma S, Malek S, Mato A, Mosse C, Shadman M, Siddiqi T, Stephens D, Sundaram S, Wagner N, Dwyer M, Sundar H. Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 4.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 18(2):185-217, 2020. e-Pub 2020. PMID: 32023533.
Mato AR, Wierda WG, Davids MS, Cheson BD, Coutre SE, Choi M, Furman RR, Heffner L, Barr PM, Eradat H, Ford SM, Zhou L, Verdugo M, Humerickhouse RA, Potluri J, Byrd JC. Utility of PET-CT in patients with chronic lymphocytic leukemia following B-cell receptor pathway inhibitor therapy. Haematologica 104(11):2258-2264, 2019. e-Pub 2019. PMID: 30923097.
Hu B, Patel KP, Chen HC, Wang X, Luthra R, Routbort MJ, Kanagal-Shamanna R, Medeiros LJ, Yin CC, Zuo Z, Ok CY, Loghavi S, Tang G, Tambaro FP, Thompson P, Burger J, Jain N, Ferrajoli A, Bose P, Estrov Z, Keating M, Wierda WG. Association of gene mutations with time-to-first treatment in 384 treatment-naive chronic lymphocytic leukaemia patients. Br J Haematol 187(3):307-318, 2019. e-Pub 2019. PMID: 31243771.
Thompson PA, Srivastava J, Peterson C, Strati P, Jorgensen JL, Hether T, Keating MJ, O'Brien SM, Ferrajoli A, Burger JA, Estrov Z, Jain N, Wierda WG. Minimal residual disease undetectable by next-generation sequencing predicts improved outcome in CLL after chemoimmunotherapy. Blood 134(22):1951-1959, 2019. e-Pub 2019. PMID: 31537528.
Brown JR, Wierda WG. Evolving Strategies in First-Line Chronic Lymphocytic Leukemia: Is There a Role for Chemoimmunotherapy?. J Natl Compr Canc Netw 17(11.5):1408-1410, 2019. e-Pub 2019. PMID: 31766019.
Strati P, Wang F, Tambaro FP, Thompson PA, Burger JA, Jain N, Ferrajoli A, Bose P, Estrov Z, Keating MJ, Futreal A, Takahashi K, Wierda WG. The landscape of genetic mutations in patients with chronic lymphocytic leukaemia and complex karyotype. Br J Haematol 187(1):e1-e4, 2019. e-Pub 2019. PMID: 31344256.
Hu B, Patel KP, Chen HC, Wang X, Wang F, Luthra R, Routbort MJ, Kanagal-Shamanna R, Medeiros LJ, Yin CC, Zuo Z, Ok CY, Loghavi S, Tang G, Tambaro FP, Thompson P, Burger J, Jain N, Ferrajoli A, Bose P, Estrov Z, Keating MJ, Wierda WG. Routine sequencing in CLL has prognostic implications and provides new insight into pathogenesis and targeted treatments. Br J Haematol 185(5):852-864, 2019. e-Pub 2019. PMID: 30924136.
Paul S, Jain N, Ferrajoli A, O'Brien S, Burger J, Keating M, Wierda W. A phase II trial of eltrombopag for patients with chronic lymphocytic leukaemia (CLL) and thrombocytopenia. Br J Haematol 185(3):606-608, 2019. e-Pub 2019. PMID: 30406944.
Thompson PA, Peterson CB, Strati P, Jorgensen J, Keating MJ, O'Brien SM, Ferrajoli A, Burger JA, Estrov Z, Jain N, Kadia TM, Borthakur G, DiNardo CD, Daver N, Jabbour E, Wierda WG. Serial minimal residual disease (MRD) monitoring during first-line FCR treatment for CLL may direct individualized therapeutic strategies. Leukemia 32(11):2388-2398, 2018. e-Pub 2018. PMID: 29769624.
Guha-Thakurta N, Wierda WG. Cerebral edema secondary to chimeric antigen receptor T-cell immunotherapy. Neurology 91(18):843, 2018. e-Pub 2018. PMID: 30373920.
Stilgenbauer S, Eichhorst B, Schetelig J, Hillmen P, Seymour JF, Coutre S, Jurczak W, Mulligan SP, Schuh A, Assouline S, Wendtner CM, Roberts AW, Davids MS, Bloehdorn J, Munir T, Böttcher S, Zhou L, Salem AH, Desai M, Chyla B, Arzt J, Kim SY, Verdugo M, Gordon G, Hallek M, Wierda WG. Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial. J Clin Oncol 36(19):JCO2017766840, 2018. e-Pub 2018. PMID: 29715056.
Jain P, Thompson PA, Keating M, Estrov Z, Ferrajoli A, Jain N, Kantarjian H, Burger JA, O'Brien S, Wierda WG. Long-term outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinib. Cancer 123(12):2268-2273, 2017. e-Pub 2017. PMID: 28171709.
Pemmaraju N, Jain P, Medeiros LJ, Jorgenson JL, Jain N, Willis J, Kontoyiannis DP, Estrov Z, Wierda WG. PET-positive lymphadenopathy in CLL - Not always Richter transformation. Am J Hematol 92(4):405-406, 2017. e-Pub 2017. PMID: 27677095.
Jain N, Balakrishnan K, Ferrajoli A, O'Brien SM, Burger JA, Kadia TM, Cortes JE, Ayres ML, Tambaro FP, Keating MJ, Gandhi V, Wierda WG. A phase I-II trial of fludarabine, bendamustine and rituximab (FBR) in previously treated patients with CLL. Oncotarget 8(13):22104-22112, 2017. e-Pub 2017. PMID: 27655665.
Lamothe B, Wierda WG, Keating MJ, Gandhi V. Carfilzomib triggers cell death in chronic lymphocytic leukemia by inducing proapoptotic and endoplasmic reticulum stress responses. Clin Cancer Res 22(18):4712-26, 2016. e-Pub 2016. PMID: 27026200.
Stilgenbauer S, Eichhorst B, Schetelig J, Coutre S, Seymour JF, Munir T, Puvvada SD, Wendtner CM, Roberts AW, Jurczak W, Mulligan SP, Böttcher S, Mobasher M, Zhu M, Desai M, Chyla B, Verdugo M, Enschede SH, Cerri E, Humerickhouse R, Gordon G, Hallek M, Wierda WG. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. Lancet Oncol 17(6):768-78, 2016. e-Pub 2016. PMID: 27178240.
Tambaro FP, Garcia-Manero G, O'Brien SM, Faderl SH, Ferrajoli A, Burger JA, Pierce S, Wang X, Do KA, Kantarjian HM, Keating MJ, Wierda WG. Outcomes for patients with Chronic Lymphocytic Leukemia (CLL) and Acute leukemia or myelodysplastic syndrome. Leukemia 30(2):325-30, 2016. e-Pub 2016. PMID: 26290497.
Thompson PA, O'Brien SM, Xiao L, Wang X, Burger JA, Jain N, Ferrajoli A, Estrov Z, Keating MJ, Wierda WG. β2 -microglobulin normalization within 6 months of ibrutinib-based treatment is associated with superior progression-free survival in patients with chronic lymphocytic leukemia. Cancer 122(4):565-73, 2016. e-Pub 2016. PMID: 26588193.
Thompson PA, Wierda WG. Eliminating minimal residual disease as a therapeutic endpoint: working toward cure for patients with CLL. Blood 127(3):279-86, 2016. e-Pub 2016. PMID: 26576865.
Kellner J, Wierda W, Shpall E, Keating M, McNiece I. Isolation of a novel chronic lymphocytic leukemic (CLL) cell line and development of an in vivo mouse model of CLL. Leuk Res 40:54-9, 2016. e-Pub 2016. PMID: 26601610.
Österborg A, Jewell RC, Padmanabhan-Iyer S, Kipps TJ, Mayer J, Stilgenbauer S, Williams CD, Hellmann A, Furman RR, Robak T, Hillmenn P, Trnený M, Dyer MJ, Piotrowska M, Kozak T, Gupta IV, Phillips JL, Goldstein N, Struemper H, Losic N, Lisby S, Wierda WG. Ofatumumab monotherapy in fludarabine-refractory chronic lymphocytic leukemia: final results from a pivotal study. Haematologica 100(8):e311-4, 2015. e-Pub 2015. PMID: 25769539.
Österborg A, Wierda WG, Mayer J, Hess G, Hillmen P, Schetelig J, Schuh A, Smolej L, Beck C, Dreyfus B, Hellman A, Kozlowski P, Pfreundschuh M, Rizzi R, Spacek M, Phillips JL, Gupta IV, Williams V, Jewell RC, Nebot N, Lisby S, Dyer MJ. Ofatumumab retreatment and maintenance in fludarabine-refractory chronic lymphocytic leukaemia patients. Br J Haematol 170(1):40-9, 2015. e-Pub 2015. PMID: 25825041.
Strati P, Keating MJ, O'Brien SM, Ferrajoli A, Burger J, Faderl S, Tambaro FP, Jain N, Wierda WG. Outcomes of first-line treatment for chronic lymphocytic leukemia with 17p deletion. Haematologica 99(8):1350-5, 2014. e-Pub 2014. PMID: 24859876.
Strati P, Keating MJ, O'Brien SM, Burger J, Ferrajoli A, Jain N, Tambaro FP, Estrov Z, Jorgensen J, Challagundla P, Faderl SH, Wierda WG. Eradication of bone marrow minimal residual disease may prompt early treatment discontinuation in CLL. Blood 123(24):3727-32, 2014. e-Pub 2014. PMID: 24705492.
Kharfan-Dabaja MA, Wierda WG, Cooper LJ. Immunotherapy for chronic lymphocytic leukemia in the era of BTK inhibitors. Leukemia 28(3):507-17, 2014. e-Pub 2014. PMID: 24157582.
Strati P, Wierda W, Burger J, Ferrajoli A, Tam C, Lerner S, Keating MJ, O'Brien S. Myelosuppression after frontline fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: Analysis of persistent and new-onset cytopenia. Cancer 119(21):3805-11, 2013. e-Pub 2013. PMID: 23943357.
Tsimberidou AM, Wierda WG, Wen S, Plunkett W, O'Brien S, Kipps TJ, Jones JA, Badoux X, Kantarjian H, Keating MJ, Research Consortium CLL. Phase I-II Clinical Trial of Oxaliplatin, Fludarabine, Cytarabine, and Rituximab Therapy in Aggressive Relapsed/Refractory Chronic Lymphocytic Leukemia or Richter Syndrome. Clin Lymphoma Myeloma Leuk 13(5):568-74, 2013. e-Pub 2013. PMID: 23810245.
Zelenetz AD, Wierda WG, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Bellam N, Byrd JC, Czuczman MS, Fayad LE, Glenn MJ, Gockerman JP, Gordon LI, Harris NL, Hoppe RT, Horwitz SM, Kelsey CR, Kim YH, Krivacic S, Lacasce AS, Nademanee A, Porcu P, Press O, Pro B, Reddy N, Sokol L, Swinnen L, Tsien C, Vose JM, Yahalom J, Zafar N, Dwyer MA, Naganuma M. Non-Hodgkin's Lymphomas, Version 1.2013. J Natl Compr Canc Netw 11(3):257-273, 2013. e-Pub 2013. PMID: 23486452.
Zelenetz AD, Wierda WG, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Bellam N, Byrd JC, Czuczman MS, Fayad L, Glenn MJ, Gockerman JP, Gordon LI, Harris NL, Hoppe RT, Horwitz SM, Kelsey CR, Kim YH, Krivacic S, LaCasce AS, Nademanee A, Porcu P, Press O, Pro B, Reddy N, Sokol L, Swinnen L, Tsien C, Vose JM, Yahalom J, Zafar N, Naganuma M, Dwyer MA. Non-Hodgkin's Lymphomas, Version 3.2012. J Natl Compr Canc Netw 10(12):1487-1498, 2012. e-Pub 2012. PMID: 23221787.
Garg R, Wierda W, Ferrajoli A, Abruzzo L, Pierce S, Lerner S, Keating M, O'Brien S. The prognostic difference of monoallelic versus biallelic deletion of 13q in chronic lymphocytic leukemia. Cancer 118(14):3531-7, 2012. e-Pub 2012. PMID: 22139735.
Kater AP, Shanafelt T, Fischer K, Wierda W. Highlights of the 6th Young Investigators' Meeting on Chronic Lymphocytic Leukemia. Leuk Lymphoma. e-Pub 2012. PMID: 22646797.
Decker WK, Shah N, Xing D, Lapushin R, Li S, Robinson SN, Yang H, Parmar S, Halpert MM, Keating MJ, Gribben JG, Molldrem JJ, Shpall EJ, Wierda WG. Generation of Functional CLL-Specific Cord Blood CTL Using CD40-Ligated CLL APC. PLoS One 7(12):e51390, 2012. e-Pub 2012. PMID: 23284688.
Badoux XC, Keating MJ, Wang X, O'Brien SM, Ferrajoli A, Faderl S, Burger J, Koller C, Lerner S, Kantarjian H, Wierda WG. Cyclophosphamide, fludarabine, rituximab and alemtuzumab (CFAR) as salvage therapy for heavily pre-treated patients with chronic lymphocytic leukemia. Blood 118(8):2085-93, 2011. e-Pub 2011. PMID: 21670470.
Parikh SA, Keating MJ, O'Brien S, Wang X, Ferrajoli A, Faderl S, Burger J, Koller C, Estrov Z, Badoux X, Lerner S, Wierda WG. Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab, and rituximab (CFAR) for high-risk chronic lymphocytic leukemia. Blood 118(8):2062-8, 2011. e-Pub 2011. PMID: 21750315.
Shah N, Decker WK, Lapushin R, Xing D, Robinson SN, Yang H, Parmar S, Tung SS, O'Brien S, Fernandez-Viña M, Shpall EJ, Wierda WG. HLA homozygosity and haplotype bias among patients with chronic lymphocytic leukemia: implications for disease control by physiological immune surveillance. Leukemia 25(6):1036-9, 2011. e-Pub 2011. PMID: 21350559.
Badoux XC, Keating MJ, Wang X, O'Brien SM, Ferrajoli A, Faderl S, Burger J, Koller C, Lerner S, Kantarjian H, Wierda WG. Fludarabine, cyclophosphamide and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL. Blood 117(11):3016-24, 2011. e-Pub 2011. PMID: 21245487.
Badoux XC, Keating MJ, Wierda WG. What is the best frontline therapy for patients with CLL and 17p deletion?. Curr Hematol Malig Rep 6(1):36-46, 2011. e-Pub 2011. PMID: 21153774.
Tong WG, Wierda WG, Lin E, Kuang SQ, Bekele BN, Estrov Z, Wei Y, Yang H, Keating MJ, Garcia-Manero G. Genome-wide DNA methylation profiling of chronic lymphocytic leukemia allows identification of epigenetically repressed molecular pathways with clinical impact. Epigenetics 5(6):499-508, 2010. e-Pub 2010. PMID: 20484983.
Tong WG, Chen R, Plunkett W, Siegel D, Sinha R, Harvey RD, Badros AZ, Popplewell L, Coutre S, Fox JA, Mahadocon K, Chen T, Kegley P, Hoch U, Wierda WG. Phase I and pharmacologic study of SNS-032, a potent and selective Cdk2, 7, and 9 inhibitor, in patients with advanced chronic lymphocytic leukemia and multiple myeloma. J Clin Oncol 28(18):3015-22, 2010. e-Pub 2010. PMID: 20479412.
Koehrer S, Keating MJ, Wierda WG. Eltrombopag, a second-generation thrombopoietin receptor agonist, for chronic lymphocytic leukemia-associated ITP. Leukemia 24(5):1096-8, 2010. e-Pub 2010. PMID: 20339441.
Faderl S, Wierda W, O'Brien S, Ferrajoli A, Lerner S, Keating MJ. Fludarabine, cyclophosphamide, mitoxantrone plus rituximab (FCM-R) in frontline CLL <70 Years. Leuk Res 34(3):284-8, 2010. e-Pub 2010. PMID: 19646755.
Alatrash G, Albitar M, O'Brien S, Wang X, Manshouri T, Faderl S, Ferrajoli A, Burger J, Garcia-Manero G, Kantarjian HM, Lerner S, Keating MJ, Wierda WG. Circulating CD52 and CD20 levels at end of treatment predict for progression and survival in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab (FCR). Br J Haematol 148(3):386-93, 2010. e-Pub 2010. PMID: 19895616.
Al-Kali A, Wierda W, Keating M, O'Brien S. Critical appraisal of the role of rituximab in the treatment of patients with previously untreated or treated chronic lymphocytic leukemia (CLL). J Blood Med 1:115-22, 2010. e-Pub 2010. PMID: 22282690.
Jain N, Wierda W, Ferrajoli A, Wong F, Lerner S, Keating M, O'Brien S. A phase 2 study of yttrium-90 ibritumomab tiuxetan (Zevalin) in patients with chronic lymphocytic leukemia. Cancer 115(19):4533-9, 2009. e-Pub 2009. PMID: 19637351.
Chen R, Wierda WG, Chubb S, Hawtin RE, Fox JA, Keating MJ, Gandhi V, Plunkett W. Mechanism of action of SNS-032, a novel cyclin dependent kinase inhibitor, in chronic lymphocytic leukemia. Blood 113(19):4637-45, 2009. e-Pub 2009. PMID: 19234140.
Balakrishnan K, Wierda WG, Keating MJ, Gandhi V. Gossypol, a BH3 mimetic, induces apoptosis in chronic lymphocytic leukemia cells. Blood 112(5):1971-80, 2008. e-Pub 2008. PMID: 18566329.
Ferrajoli A, Wierda WG, LaPushin R, O'Brien SM, Faderl S, Browning ML, Keating MJ. Pilot experience with continuous infusion alemtuzumab in patients with fludarabine-refractory chronic lymphocytic leukemia. Eur J Haematol 80(4):296-8, 2008. e-Pub 2008. PMID: 18182081.
Tsimberidou AM, Wierda WG, Plunkett W, Kurzrock R, O'Brien S, Wen S, Ferrajoli A, Ravandi-Kashani F, Garcia-Manero G, Estrov Z, Kipps TJ, Brown JR, Fiorentino A, Lerner S, Kantarjian HM, Keating MJ. Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol 26(2):196-203, 2008. e-Pub 2008. PMID: 18182662.
Tam CS, O'Brien S, Lerner S, Khouri I, Ferrajoli A, Faderl S, Browning M, Tsimberidou AM, Kantarjian H, Wierda WG. The natural history of fludarabine-refractory chronic lymphocytic leukemia patients who fail alemtuzumab or have bulky lymphadenopathy. Leuk Lymphoma 48(10):1931-1939, 2007. e-Pub 2007. PMID: 17917961.
Tam C, Wierda W, Lerner S, Keating M. Chronic lymphocytic leukemia: How do you assess prognosis in 2007?. Clinical Leukemia 1(3):162-167, 2007. e-Pub 2007.
Motta M, Rassenti L, Shelvin BJ, Lerner S, Kipps TJ, Keating MJ, Wierda WG. Increased expression of CD152 (CTLA-4) by normal T lymphocytes in untreated patients with B-cell chronic lymphocytic leukemia. Leukemia 19(10):1788-93, 2005. e-Pub 2005. PMID: 16094420.
Balakrishnan K, Wierda WG, Keating MJ, Gandhi V. Mechanisms of cell death of chronic lymphocytic leukemia lymphocytes by RNA-directed agent, 8-NH2-adenosine. Clin Cancer Res 11(18):6745-6752, 2005. e-Pub 2005. PMID: 16166456.
Keating MJ, Rai KR, Wierda WG. Evolution of treatment strategies in chronic lymphocytic leukemia. Part 2 of a 3-Part series: Advances in the treatment of hematologic malignancies. Clin Adv Hematol Oncol 3(8):1-10; quiz 11-2, 2005. e-Pub 2005. PMID: 16201050.
Battle TE, Wierda WG, Rassenti LZ, Zahrieh D, Neuberg D, Kipps TJ, Frank DA. In vivo activation of signal transducer and activator of transcription 1 after CD154 gene therapy for chronic lymphocytic leukemia is associated with clinical and immunologic response. Clin Cancer Res 9(6):2166-2172, 2003. e-Pub 2003. PMID: 12796382.
McCarthy H, Wierda WG, Barron LL, Cromwell CC, Wang J, Coombes KR, Rangel R, Elenitoba-Johnson KS, Keating MJ, Abruzzo LV. High expression of activation-induced cytidine deaminase (AID) and splice variants is a distinctive feature of poor prognosis chronic lymphocytic leukemia. Blood 101(12):4903-4908, 2003. e-Pub 2003. PMID: 12586616.
Cantwell MJ, Wierda WG, Lossos IS, Levy R, Kipps TJ. T cell activation following infection of primary follicle center lymphoma B cells with adenovirus encoding CD154. Leukemia 15(9):1451-1457, 2001. e-Pub 2001. PMID: 11516107.
Chu P, Wierda WG, Kipps TJ. CD40 activation does not protect chronic lymphocytic leukemia B cells from apoptosis induced by cytotoxic T lymphocytes. Blood 95(12):3853-3858, 2000. e-Pub 2000. PMID: 10845920.
Dato ME, Wierda WG, Kim YB. A triggering structure recognized by G7 monoclonal antibody on porcine lymphocytes and granulocytes. Cell Immunol 140(2):468-477, 1992. e-Pub 1992. PMID: 1544170.
Kim JW, Wierda WG, Kim YB. Immobilized IgG immune complex induces secretion of tumor-necrosis-factor-alpha by porcine alveolar macrophages. Am J Respir Cell Mol Biol 5(3):249-255, 1991. e-Pub 1991. PMID: 1832880.
Johnson BD, Wierda WG, Kim YB. Further characterization of PNK-E: a monoclonal antibody enhancing porcine natural killer cell activity. Cell Immunol 134(2):378-389, 1991. e-Pub 1991. PMID: 2021974.

Invited Articles

Wierda WG. ASCO 2008 Editorial Season Review. e-Pub 2008.
Tam C, Wierda W. Salvage chemoimmunotherapy for patients with relapsed / refractory chronic lymphocytic leukemia. Am Jour of Onc Rev 5(8):2-5, 2006. e-Pub 2006.
Tam C, Wierda W. Combining biologic agents in CLL - rationale and clinical status. Chronic Lymphocytic Leukemia - The Cutting Edge 11(3):7-10, 2006. e-Pub 2006.
Carney DA, Wierda WG. Genetics and molecular biology of chronic lymphocytic leukemia. Curr Treat Options Oncol 6(3):215-225, 2005. e-Pub 2005. PMID: 15869733.
Keating MJ, Rai KR, Wierda WG. Evolution of treatment strategies in chronic lymphocytic leukemia. Part 2 of a 3-part series: Advances in the treatment of hematologic malignancies. Clin Adv Hematol Oncol 3(8):1-10, 2005. e-Pub 2005.
Wierda, WG, OBrien SM, Keating MJ. Rituximab in the management of patients with untreated or relapsed chronic lymphocytic leukemia. Monographs in Leukemia 5(1):8-14, 2004. e-Pub 2004.
Kipps TJ, Chu P, Wierda WG. Immunogenetic therapy of B-cell malignancies. Semin Oncol 27(6 Suppl 12):104-109, 2001. e-Pub 2001.
Kim YB, Dato ME, Johnson BD, Wierda WG. Development and regulation of porcine natural killer cells. Proceedings of Xth International Symposium on Gnotobiology, 1990. e-Pub 1990.

Editorials

Allan JN, Flinn IW, Siddiqi T, Ghia P, Tam CS, Kipps TJ, Barr PM, Elinder Camburn A, Tedeschi A, Badoux XC, Jacobs R, Kuss BJ, Trentin L, Zhou C, Szoke A, Abbazio C, Wierda WG. Outcomes in Patients with High-Risk Features after Fixed-Duration Ibrutinib plus Venetoclax: Phase II CAPTIVATE Study in First-Line Chronic Lymphocytic Leukemia. Clin Cancer Res 29(14):2593-2601, 2023. PMID: 37282671.
Wierda WG. Ibrutinib Plus Venetoclax for First-Line Chronic Lymphocytic Leukemia Treatment. NEJM Evid 1(7):EVIDe2200093, 2022. PMID: 38319264.

Abstracts

Siddiqi T, JDi S, Dorritie KA, Stephens DM, Riedell PA, Arnason J, Kipps TJ, Gillenwater HH, Gong L, Yang K, Ogasawara K, Thorpe J, Wierda WG. Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL. Blood 139(12):1794-1806, 2022. e-Pub 2022.
Osterberg A, Dyer MJS, Mayer J, Hess G, Hillmen P, Schetelig, Schuh A, Smolej L, Beck C, Dreyfus B, Hellman A, Koslowski P, Pfreundschuh M, Rizzi R, Spacek M, Chan G, Gupta I, Phillips J, Lisby S, Wierda WG. Ofatumumab retreatment and maintenance in patients with fludarabine-refractory CLL. J Clin Oncol 30, 2012. e-Pub 2012.
Tambaro FP, Wierda WG, Garcia-Manero G, Cortes JE, Pierce S, Annunziata M, Ripaldo M, Borthakur G, Jabbour E, Randi F, Faderl S, Kantarjian H. Factors associated with outcome of secondary MDS and AML: Review of 2,182 patients at MDACC. J Clin Oncol 30, 2012. e-Pub 2012.
Lee HJ, Wierda WG, Ferrajoli A, Burger JA, Trinh L, Lerner S, Keating MJ, O'Brien SM. Comparison of fludarabine (F), cyclophosphamide (C), and rituximab (R) versus FCR plus bevacizumab (B) in relapse chronic lymphocytic leukemia (CLL). J Clin Oncol 30, 2012. e-Pub 2012.
Tambaro FP, Wierda WG, Pierce S, Yang H, Wei Y, Fang Z, Kantarjian HM, Garcia-Manero G. ROS Activation Independent From Iron Overload in MDS. Blood 118, 2011. e-Pub 2011.
Tambaro FP, Garcia-Manero G, Faderl S, O'Brien S, Ferrajoli A, Burger JA, Trinh LX, Lerner S, Kantarjian HM, Keating MJ, Wierda WG. Acute Leukemia and Myelodysplastic Syndrome: Outcomes in Patients with Chronic Lymphocytic Leukemia (CLL) at MD Anderson Cancer Center (MDACC). Blood 118, 2011. e-Pub 2011.
Parikh SA, Keating M, O'Brien S, Ferrajoli A, Faderl S, Koller C, Estrov Z, Lerner S, Wierda WG. Frontline Combined Chemoimmunotherapy with Fludarabine, Cyclophosphamide, Alemtuzumab and Rituximab (CFAR) in High-Risk Chronic Lymphocytic Leukemia. Blood 114(22):91, 2009. e-Pub 2009.
Badoux XC, Keating M, O'Brien S, Ferrajoli A, Burger JA, Faderl S, Garcia-Manero G, Kadia T, Abruzzo LV, Wierda WG. Patients with Relapsed CLL and 17p Deletion by FISH Have Very Poor Survival Outcomes. Blood 114(22):513, 2009. e-Pub 2009.
Keating MJ, Wierda WG, Tam CS, Kantarjian HM. Long Term Outcome following Treatment Failure of FCR Chemoimmunotherapy as Initial Therapy for Chronic Lymphocytic Leukemia. Blood 114(22):940, 2009. e-Pub 2009.
Badoux XC, Keating M, O'Brien S, Kadia T, ferrajoli A, Faderl S, Koller C, Garcia-Manero G, Burger JA, Wierda WG. Chemoimmunotherapy with Cyclophosphomide, Fludarabine, Alemtuzumab and Rituximab (CFAR) Is Effective in Relapsed Patients with Chronic Lymphocytic Leukemia (CLL). Blood 114(22):1332, 2009. e-Pub 2009.
Osterborg A, Biilmann Ronn B, Jewell RC, Kipps TJ, Mayer J, Stilgenbauer S, Williams CD, Hellmann A, Robak T, Furman RR, Hillman P, Trneny M, Dyer M JS, Padmanabham S, Piotrowska M, Kozak T, chan G, Arning M, Losic N, Davis R, Wilms J, Russell CA, Wierda WG. Correlation Between Serum Ofatumumab Concentrations, Baseline Patient Characteristics and Clinical Outcomes in Patients with Fludarabine-Refractory Chronic Lymphocytic Leukemia (CLL) Treated with Single-Agent Ofatumumab. Blood 114(22):1334, 2009. e-Pub 2009.
Tsimberidou AM, Wierda W, Plunkett W, O'Brien S, Kipps TJ, Jones JA, Smith S, Jalayer A, Kantarjian HM, Keating M. Oxaliplatin, Fludarabine, Cytarabine, and Rituximab Combination Therapy Induces High Response Rates in Agressive Chronic Lymphocytic Leukemia (CLL) and Richter's Syndrome (RS). Blood 114(22):1337, 2009. e-Pub 2009.
Batty N, Badoux XC, Keating M, Lin E, Lerner S, O'Brien S, Ferrajoli A, Kadia T, Burger JA, Faderl S, Wierda WG. Pretreatment Factors Associated with Second Malignancies Occuring After Frontline Fludarabine, Cyclophosphamide, and Rituximab (FCR) in Patients with Chronic Lymphocytic Leukemia (CLL). Blood 114(22):1339, 2009. e-Pub 2009.
Tsimberidou AM, Wierda WG, Plunket WK, O'Brien S, Lerner S, Smith SC, Kantarjian HM, Keating MJ. Phase I/II study of oxaliplatin, fludarabine, cytarabine, and rituximab in patients (OFAR2) with Richter's syndrome (RS), and relapsed or refractory B-cell chronic lymphocytic leukemia (CLL). Jour of Clin Oncol 27(15S):363s, 2009. e-Pub 2009.
Kipps TJ, Osterborg A, Mayer J, Stilgenbauer S, Hellmann A, Williams CD, Furman R, Chan G, Russell C, Wierda WG. Clinical improvement with a novel CD20 mAb, ofatumumab, in fludarabine-refractory chronic lymphocytic leukemia (CLL) also refractory to alemtuzumab or with bulky lymphadenopathy. Journal of Clinical Oncology 27(15S):366s, 2009. e-Pub 2009.
Osterborg A, Kipps TJ, Mayer J, Stilgenbauer S, Williams CD, Hellmen A, Robak T, Furman RR, Hillmen P, Trneny M, Dyer MJS, Padmanabham S, Kozak T, Chan G, Davis RL, Losic N, Russell CA, Piotrowska M, Wilms J, Wierda WG. Ofatumumab (HuMax-CD20), a Novel CD20 Monoclonal Antibody, Is An Active Treatment for Patients with CLL Refractory to Both Fludarabine and Alemtuzumab or Bulky Fludarabine-Refractory Disease: Results from the Planned Interim analysis of An International Pivotal Study. Blood 112(11):126, 2008. e-Pub 2008.
Henderson JD, O'Brien SM, Wang X, Faderl SH, Ferrajoli A, Garcia-Manero G, Tam CS, Burger JA, Abruzzo LV, Schlette E, Lerner S, Keating MJ, Wierda WG. Integrating Newer Prognostic Factors in Evaluation of Previously Treated Patients with CLL Receiving Salvage Treatment. Blood 112(11):723, 2008. e-Pub 2008.
Tam CS, Wierda WG, O'Brien S, Lerner S, Khouri IF, Kantarjian HM, Keating M. Life after Fludarabine, Cyclophosphamide, & Rituximab (FCR) - the Clinical Outcome of Patients with Chronic Lymphocytic Leukemia Who Receive Salvage Treatment after Frontline FCR. Blood 112(11):727, 2008. e-Pub 2008.
Keating MJ, Lerner S, Wang X, Rassenti LZ, O'Brien S, Kipps TJ, Wierda WG. Predicting Time to Initial Treatment in Early Stage CLL - Integration of Classical and Novel Prognostic Factors. Blood 112(11):728, 2008. e-Pub 2008.
Tam CS, Wierda W, O'Brien SM, Lerner S, Abruzzo LV, Ferrajoli A, Kantarjian HM, Keating MJ. The clinical significance of chromosome 17p deletion in chronic lymphocytic leukemia: A study of 180 consecutive patients. Supplement to Journal of Clinical Oncology 2008 ASCO Annual Meeting 26(15S/Part I of II):380s, 2008. e-Pub 2008.
Faderl S, Wierda W, Ferrajoli A, O'Brien S, Ravandi F, Kantarjian H, Showalter B, Lerner S, Keating M. Update of Experience with Fludarabine, Cyclophosphamide, Mitoxantrone Plus Rituximab (FCM-R) in Frontline Therapy for Chronic Lymphocytic Leukemia (CLL). Blood 110(11):193a, 2007. e-Pub 2007.
Tam C, Keating M, O'Brien S, Ferrajoli A, Abruzzo L, Lerner S, Faderl S, Kantarjian H, Wierda W. The Natural History and Treatment Outcomes of De-Novo Chromosome 17p Deletion CLL: A Single Institution Experience with 48 Patients. Blood 110(11):608a, 2007. e-Pub 2007.
Tam C, Keating M, Tsimberidou A, O'Brien S, Ferrajoli A, Lerner S, Abruzzo L, Schlette E, Kantarjian H, Wierda W. The Clinical Usefulness of Novel Prognostic Factors in CLL: A study of 477 Patients with Low-Risk (Non-11q, Non-17p) FISH and Known IGVH Mutation Status. Blood 110(11):905a, 2007. e-Pub 2007.
Tong W, Wierda W, Bekele N, Kuang S, Keating M, Garcia-Manero G. Genome-Wide DNA Methylation Profile of CLL with 17p del Allowed Identification of Multiple Epigenetically Inactivated Molecular Pathways with Prognostic Value in Human Leukemia. Blood 110(11):152a, 2007. e-Pub 2007.
Chen R, Wierda W, Benaissa S, Hoch U, Hawtin R, Fox J, Keating M, Gandhi V, Plunkett W. Mechanism of Action of SNS-032, A Novel Cyclin Dependent Kinase Inhibitor, in Chronic Lymphocytic Leukemia: Comparison with Flavopiridol. Blood 110(11):915a, 2007. e-Pub 2007.
Alatrash G, Keating M, O'Brien S, Wang X, Manshouri T, Faderl S, Ferrajoli A, Kantarjian H, Lerner S, Wierda W. Circulating CD52 and CD20 levels predict for progression and survival in patients with CLL treated with fludarabine (F), cyclophosphamide (C), and rituximab (FCR). Blood 108(11):660a, 2006. e-Pub 2006.
Tsimberidou A, Wierda W, O'Brien S, Plunkett W, Kipps T, Brown J, Lerner S, Kantarjian H, Keating M. Combination of oxaliplatin, fludarabine, cytarabine, and rituximab in Richter's syndrome and fludarabine-refractory chronic lymphocytic leukemia. Blood 108(11):799a, 2006. e-Pub 2006.
Faderl S, Wierda W, O'Brien S, Ferrajoli A, Ravandi-Kashani F, Detry M, Kantarjian H, O'Neal B, Keating M. Fludarabine, cyclophosphamide, mitoxantrone plus rituximab (FCM-R) as frontline therapy for CLL: results of a Phase II study. Blood 108(11):803a, 2006. e-Pub 2006.
Faderl S, Wierda W, Ferrajoli A, O’Brien S, Garcia-Manero G, Thomas D, Kantarjian H, Browning M, Lerner S, Keating M, et al. Alemtuzumab (continuous infusion followed by subcutaneous injection) plus rituximab is active in patients (pts) with relapsed/refractory chronic lymphocytic leukemia (CLL) – an update of the MDACC experience. 9th International Conference on Malignant Lymphoma, Lugano, Switzerland, 2005. e-Pub 2005.
Motta M, Wierda W, O'Brien S, Faderl S, Ferrajoli A, Detry M, Lerner S, Kantarjian H, Keating M. Infections in patients with chronic lymphocytic leukemia treated with chemoimmunotherapy. Blood 106(11):213a, 2005. e-Pub 2005.
O'Brien S, Wierda W, Faderl S, Ferrajoli A, Bueso-Ramos C, Brown M, Kantarjian H, Keating M. FCR-3 as frontline therapy for patients with chronic lymphocytic leukemia (CLL). Blood 106(11):599a, 2005. e-Pub 2005.
Motta M, Shelvin B, Lerner S, Keating M, Wierda WG. Increased expression of CD152 by normal T lymphocytes in untreated patients with B cell chronic lymphocytic leukemia. Blood 104(11):276a, 2004. e-Pub 2004.
Castro J, Wierda W, Kipps T, Keating M, Bole J, Anderson B, Meyer J, Bonyhadi M, Berenson R, Frohlich M. A Phase 1/11 trial of Xcellerated T Cells™ in patients with chronic lymphocytic leukemia. Blood 104(11):687a, 2004. e-Pub 2004.
Spoo A, Wierda W, Burger J. The CXCR4 Score: A new prognostic marker in acute myelogenous leukemia. Blood 104(11):304a, 2004. e-Pub 2004.
Yee KWL, Wierda W, OBrien S, Thomas D, Kurzrock R, Fayad LE, Hagemeister FB, Cortes J, Prestifilippo J, Szatrowski TP, Kantarjian HM, Giles FJ. A Phase 1/11 study of the oral mTOR inhibitor RAD001 in patients with advanced hematologic malignancies. Blood 104(11):2876, 2004. e-Pub 2004.
O'Brien S, Wierda W, Geisler D, Lerner S, Albitar M, Keating M. Yttrium-90 ibritumomab tiuxetan for minimal residual disease in CLL. JCO 22:631a, 2003. e-Pub 2003.
Thomas D, Wierda W, Faderl S, OBrien S, Kornblau S, Koller C, Bantia S, Kiltpatrick M, Bennett C, Kantarjian H, Gandhi V. Preliminary activity of intravenous BCX-1777 in aggressive T-Cell malignancies. Blood 102(11):261b, 2003. e-Pub 2003.
McCarthy H, Wierda W, Barron L, Cromwell, Keating M, Abruzzo L. Chronic lymphocytic leukemia (CLL) patients with unmutated immunoglublin VH genes express high levels of activation-induced cytidine deaminase (AICD) mRNA and splice variants. Blood 100(11):99a, 2001. e-Pub 2001.
Wierda WG, Jacobs R, Barr PM, Allan JN, Siddiqi T, Tedeschi A, Kipps TJ, O'Brien SM, Badoux XC, Visentin A, Lasica M, Carney D, Camburn AE, Torroba JD, Szafer-Glusman E, Zhou C, Szoke A, Dean JP, Ghia P, Tam CS. Outcomes in high-risk subgroups after fixed-duration ibrutinib + venetoclax for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): up to 5.5 years of follow-up in the phase 2 CAPTIVATE study. Journal of Clinical Oncology.

Book Chapters

Wierda, WG. Promising combinations of drugs targeting apoptosis. In: Volume 1 - Targeting Oncogenic Drivers and Signaling Pathways in Lymphoid Malignancies: From Concept to Practice. Wiley, 186-196, 2023.
Cortes JE, Kantarjian H, Wierda W. Chronic Leukemias. In: Conn's Current Therapy. W. B. Saunders Company Publications, 456-463, 2009.
Wierda, WG. Gene Therapy, Vaccines and Immune Modulation. In: Chronic Lymphocytic Leukemia. Informa Healthcare, 2008.

Less

Selected Presentations & Talks

Local Presentations

2025. Evolving Strategies in CLL Treatment, Part 2. Invited. Leukemia Research Meeting. Houston, Texas, US.
2025. Evolving Strategies in CLL Treatments. Invited. Hematology Grand Rounds. Houston, Texas, US.
2024. Opportunities for Advances in CLL. Invited. Hematology Grand Rounds. Houston, Texas, US.
2019. Next Questions: Chronic Lymphocytic Leukemia. Conference. JWC Covenant, Inc. Houston, TX, US.
2019. Changing the treatment paradigm for CLL- Chemoimmunotherapy. Conference. CancerNet. Houston, TX, US.
2019. CLL Patient Forum. Conference. CLL Society. Houston, TX, US.
2018. Overview of CLL. Conference. Baylor College of Medicine. Houston, TX, US.
2018. Overview of Treatment Options for CLL. Conference. CancerNet. Houston, TX, US.
2017. CLL – Novel Strategies. Conference. MD Anderson Physicians Network. Houston, TX, US.
2017. Managing BTK Inhibitor Refractory CLL - A Case Study. Conference. Society of Hemotologic Oncology (SOHO). Houston, TX, US.
2016. How I Treat patients with High-Risk CLL. Conference. UT MD Anderson Cancer Center. Houston, TX, US.

Regional Presentations

2024. CLL. Invited. Hematology/Oncology Fellows Lecture Series, US.
2019. What Informs Our Clinical Decisions in CLL Management? Key Evidence to Stratify Risk and Optimize Sequencing. Conference. PER. Cranbury, NJ, US.
2019. CLL: An Overview. Conference. HOLI - Aptitude Health. Atlanta, GA, US.
2017. Value of MRD in CLL in Routine Practice. Conference. Canadian CLL Research Meeting. Winnipeg, CA.

National Presentations

2025. Updates in CLL. Invited. West Oncology Conference. Memphis, TN, US.
2024. Breyanzi Chronic Lymphocytic Leukemia KOL National Launch Meeting-Virtual. Conference. 2024 FL Strategic Council-Event. Virtual, US.
2023. Pirtobrutinib in Richter Transformation: Updated Efficacy and Safety Results with 18-Month Median Survival Follow-up from the Phase 1/2 BRUIN Study. Invited. Eli Lilly and Company. San Diego, CA, US.
2023. Pirtobrutinib, CAR T, and others. How to incorporate it in practice?. Conference. Binaytara Foundation. Nashville, TN, US.
2023. Novel Therapies of Ricters. Invited. Society of Hematologic Oncology (SOHO). Houston, TX, US.
2023. Treatment of Patients with P53 aberrantions. Invited. MD Education USA. La Jolla, CA, US.
2023. NCCN CLL/SLL/Hairy Cell Leukemia Panel Meeting. Conference. National Comprehensive Cancer Network (NCCN). Plymouth, PA, US.
2023. Chronic Lymphocytic Leukemia. Conference. 19th Miami Cancer Meeting. Miami, FL, US.
2023. Scientific Advisory Board- 2023 ONC Hematology Global Medical Scientific Advisory Board. Invited. Eli Lilly and Company. New York, NY, US.
2023. Physician Session Title: Emerging Therapy for Relapsed and Refractory Chronic Lymphocytic Leukemia. Invited. 20th Annual Indy Hematology Review. Indianapolis, IN, US.
2023. Moderator CLL: An Interactive Local Workshop. Invited. Curio Science. Virtual, US.
2022. Workup of CLL in the Era of Small Molecules - Breakfast with the Expert II. Invited. Society of Hematologic Oncology (SOHO 2022). Houston, TX, US.
2022. BRUIN CLL-322: A phase 3 open-label, randomized study of fixed duration pirtobrutinib plus venetoclax and rituximab versus venetoclax and rituximab in previously treated chronic lymphocytic leukemia/small lymphocytic leukemia (Trial in Progress). Invited. Eli Lilly. Houston, TX, US.
2022. Moderator - AstraZeneca Optimizing CLL Treatment Selection in an Evolving Treatment Landscape Advisory Board. Invited. AstraZeneca. Houston, TX, US.
2022. Update on CLL Strategy. Conference. Roche, US.
2022. CLL - Immune Effectors, CAR-T, and Bispecific Therapies Across Heme Malignancies. Invited. Physicians' Education Resource (PER). New York, NY, US.
2022. Chair - Hematology Session III and Presentation: Learning from BTK Inhibitors & Moving Forward the Therapeutic Field in CLL. Invited. New Orleans Summer Cancer Meeting (NOSCM). New Orleans, LA, US.
2022. NCCN CLL/SLL/Hairy Cell Leukemia Panel Meeting. Invited. National Comprehensive Cancer Network (NCCN). Plymouth Meeting, PA, US.
2022. Answers Now: CLL Drug Resistance and Intolerance. Conference. Patient Power - videoconference, US.
2021. Chair: Elucidating Novel BTKi Strategies in CLL/SLL and MCL. Invited. Physicians' Education Resource (PER). Atlanta, GA, US.
2021. Chair - Medical Crossfire: How Are We Meeting the Needs of Patients with CLL Across Lines of Care. Invited. Physicians' Education Resource (PER). Houston, TX, US.
2021. Chronic Lymphocytic Leukemia. Invited. Appsvenue - Kuwait, US.
2021. Working Towards Curative Strategies for Patients with CLL. Invited. Fred Hutch/UW Medical Oncology and Clinical Research Division, US.
2021. Pharmacyclics Virtual Resistance Advisory Board. Invited. Pharmacyclics, Inc, US.
2021. Chair - MCL/ALL Regional Advisory Board. Invited. Kite Pharma, Inc, US.
2021. Medical Crossfire: What are the Key Patient and Tumor Specific Features that Drive Your Initial and Subsequent Decisions in CLL?. Invited. Physicians' Education Resource (PER), US.
2019. Present and Future Therapies for Chronic Lymphocytic Leukemia. Conference. MAYO Clinic. Rochester, MN, US.
2019. Evolving Strategies in First-Line CLL; Is there a Role for Chemoimmunotherapy?. Invited. NCCN. San Francisco, CA, US.
2019. "Relapsed/Refractory CLL/sLL Management". Conference. Medallion Healthcare. Dallas, TX, US.
2019. “The Changing Face of CLL Treatment - Moving with the Times”. Invited. Medscape Education. New York, NY, US.
2019. “Promises, Promises: Information Long-term Expectation in WM and CLL”. Conference. “Promises, Promises: Information Long-term Expectation in WM and CLL”. Chicago, IL, US.
2019. General disease state and treatment guidelines. Conference. Bio Ascend, LLC, AstraZeneca, Bayer, Celgene Corp, Gilead Sciences, US.
2019. Relapsed/Refractory Chronic Lymphocytic Leukemia: Cure or Long-Term Remission?. Invited. Physicians' Education Resource (PER). Miami, FL, US.
2019. Updates in CLL. Invited. Scripps Conference Services & CME. San Diego, CA, US.
2018. Assessment of R3esidual Disease (MRD): Should MRD be a milestone?. Conference. Leukemia Master Class. Dallas, TX, US.
2018. Cart-T MTP Session. Invited. SOHO, US.
2017. Review of current available evidence of the correlation between biomarker status in CLL and response to therapy and prognosis. Conference. Florida Cancer Specialist (FCS). Orlando, FL, US.
2017. How to Sequence Therapy in Chronic Lymphocytic Leukemia. Conference. NCCN Hematologic Malignancies Conference. San Francisco, CA, US.
2016. Assessing Key Factors when Choosing Initial Therapy for Patients with Chronic Lymphocytic Leukemia. Invited. Chemotherapy Foundation Symposium. New York, NY, US.
2016. Debate—Examining Controversies in the Front-line Management of CLL: Chemo-immunotherapy vs. Continuous TKI Therapy. Invited. National Comprehensive Cancer Network. New York, NY, US.
2013. BTK Inhibitors, PI3K Inhibitors, Etc - Novel Therapies for CLL. Conference. 2013 ASH State-of-the-Art Symposium. Chicago, IL, US.
2013. Novel Agents in CLL. Invited. Society of Hematologic Oncology. Houston, TX, US.
2013. New Therapies. Invited. Society of Hematologic Oncology. Houston, TX, US.
2013. Core D Clinical Update. Conference. Chronic Lymphocytic Leukemia Research Consortium (CRC). Coronado, CA, US.
2013. ROR1 CAR Update. Conference. Chronic Lymphocytic Leukemia Research Consortium (CRC). Coronado, CA, US.
2012. CLL: Immunotherapy in CLL. Invited. Houston 2012 Hematologic Malignancies Conference. Houston, TX, US.
2012. MTP Session VIII: CLL Biology and Therapy - Biology and Prognostic Factors. Invited. Houston 2012 Hematologic Malignancies. Houston, TX, US.
2012. Utility of Prognostic and Predictive Factors in Management of Patients with CLL. Conference. 16th Annual Int'l Congress on Hematologic Malignancies. Snowbird, UT, US.
2012. Chronic Lymphocytic Leukemia (CLL). Invited. Leukemia & Lymphoma Society. Omaha, NE, US.
2012. Immune Stimulation. Conference. CLL Research Consortium (CRC) Annual Meeting. La Jolla, CA, US.
2012. Chronic Lymphocytic Leukemia. Conference. 2012 Highlights of ASH in North America. New York, NY, US.
2011. A Phase I/II Trial of Fludarabine, Bendamustine, and Rituximab (FBR) Chemoimmunotherapy for Previously Treated Patients with CLL - Poster Presentation. Conference. American Society of Hematology Annual Meeting 2011. San Diego, CA, US.
2011. Pretreatment Patient Characteristics Associated with Achieving Bone Marrow Minimal Residual Disease-Free Status with Frontline Fludarabine, Cyslosphosphamide, Rituximab (FCR) Chemoimmunotherapy for CLL - Poster Presentation. Conference. American Society for Hematology Annual Meeting 2011. San Diego, CA, US.
2011. Correlations Between Ofatumumab Exposure and Treatment Outcomes for Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Frontline Ofatumumab, Fludarabine, and Cyclophosphamide Chemoimmunotherapy - Poster Presentation. Conference. American Society of Hematology Annual Meeting 2011. San Diego, CA, US.
2011. State of the art and perspectives. Invited. XIV iwCLL 2011. Houston, TX, US.
2011. Phase 2 Study of Navitoclax (ABT-263) Safety and Efficacy in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: Interim Results. Conference. Society of Hematologic Oncology. Houston, TX, US.
2011. Impact of Bone Marrow Microenvironment on 93 Apoptotic Pathway Target mRNA Expression in CLL Cells. Conference. Society of Hematologic Oncology. Houston, TX, US.
2011. HDAC-Mediated Silencing of miR-17 and miR-20a in Chronic Lymphocytic Leukemia. Conference. Society of Hematologic Oncology. Houston, TX, US.
2011. Disease Characteristics and Response to First Therapy in African American Patients with CLL: the M.D. Anderson Cancer Center Experience. Conference. Society of Hematologic Oncology. Houston, TX, US.
2011. Sap+Cyclo+R (11q-). Conference. Chronic Lymphocytic Leukemia Research Consortium (CRC). La Jolla, CA, US.
2011. ROR-1 CAR. Conference. Chronic Lymphocytic Leukemia Research Consortium. La Jolla, CA, US.
2011. CRC Clinical Trial Concepts. Conference. Chronic Lymphocytic Leukemia Research Consortium (CRC). La Jolla, CA, US.
2010. New Advances in CLL Management. Conference. 4th Annual Mid-America Cancer Symposium. Wichita, KS, US.
2010. Chronic Lymphocytic Leukemia: Novel Therapies. Conference. 2010 Highlights of ASH. Marina del Rey, CA, US.
2010. Risk Stratified Treatment for CLL. Conference. 6th Annual Clinical Breakthroughs & Challenges in Hamatologic Malignancies. Lake Buena Vista, FL, US.
2009. Emerging Agents for Chronic Lymphocytic Leukemia: Addressing Unmet Needs for Therapy. Conference. Physicians' Education Resource. Dallas, TX, US.
2009. New Treatments for CLL - Q & A. Invited. GlaxoSmithKline. Scottsdale, AZ, US.
2009. Update on Prognostic Factors and Current Treatments for Patients with Chronic Lymphocytic Leukemia (CLL). Invited. The University of Texas M. D. Anderson Cancer Center. Houston, TX, US.
2009. Therapeutic Agents in CLL: Review and Discussion. Conference. Genentech, Inc. Dallas, TX, US.
2009. Focusing on CLL. Conference. Physicians' Education Resource. Dallas, TX, US.
2009. Review of clinical trial data (FC v FCR, PCR v FCR). Invited. National Comprehensive Cancer Network. Philadelphia, PA, US.
2009. Emerging Treatment Paradigms in the Management of Chronic Lymphocytic Leukemia. Invited. Educational Concepts Group, LLC. McKinney, TX, US.
2009. Symposium on Emerging Therapies in Lymphoproliferative Diseases: BCL-2 inhibitors. Invited. Great Debates and Updates in Hematologic Malignancies. Boca Raton, FL, US.
2009. Debate: No "Should CLL/SLL sub-groups that have deletion 17p or who have the best prognostic features be treated differently than the average CLL/SLL patient?. Invited. Great Debates and Updates in Hematologic Malignancies. Boca Raton, FL, US.
2009. Strategies for optimizing Rituxan clinical utility in CLL based on REACH and CLL-8 data. Invited. Genentech. Dallas, TX, US.
2009. ASH Review. Invited. University of Nebraska Medical Center. Omaha, NE, US.
2009. The development of Rituxan treatment in CLL including the initial monotherapy studies leading to combination treatment with fludarabine and subsequently fludarabine and cyclophosphamide. Invited. Regional Advisory Board/Review Article. Las Vegas, NV, US.
2008. Poster Presentation "Plasma Alemtuzumab Levels at End of Treatment Correlate with Response and Response Duration in Patients with CLL Receiving Treatment for Residual Disease". Invited. American Society of Hematologists. San Francisco, CA, US.
2008. Poster Presentation "Active Immune Gene Therapy Using ISF35: Responses Associated with Priming for Death Receptor-Induced Apoptosis and Sensitivity to Fludarabine in Patients with CLL and Del 17p". Invited. American Society of Hematologists. San Francisco, CA, US.
2008. Poster Presentation "CFAR, An Active Frontline Regimen for High-Risk Patients with CLL, Including Those with Del 17p". Invited. American Society of Hematologists. San Francisco, CA, US.
2008. Poster Presentation "Integrating Newer with Traditional Prognostic Factors in Evaluating Patients with CLL Receiving Frontline Chemoimmunotherapy". Invited. American Society of Hematologists. San Francisco, CA, US.
2008. Rituxan in the treatment of CLL. Invited. Genentech Advisory Board Moderator Workshop. San Francisco, CA, US.
2008. Emerging Treatment Paradigms in the Management of CLL. Invited. Meeting of the Division of Neoplastic Diseases & Related Disorders. Milwaukee, WI, US.
2008. Prognostic Factors - Directing Treatment Strategies. Invited. Leukemia 2008. Houston, TX, US.
2008. 406 Study Background: Unmet Need in Fludarabine Refractory CLL. Invited. Leukemia 2008. Houston, TX, US.
2008. Advisory Panel Member. Invited. NCCN Non-Hodgkin's Lymphoma Panel Meeting. Philadelphia, PA, US.
2008. Advisor. Invited. Abraxis Bioscience Pipeline Council Meeting. Los Angeles, CA, US.
2008. The Role of Revlimid (lenalidomide) in del 5q Myelodysplastic Syndromes. Invited. Revlimid Promotional Speakers Bureau Meeting. Houston, TX, US.
2008. Expanding Horizons: Advances in Targeted Therapies for CLL. Invited. Campath Promotional Dinner Meeting. Costa Mesa, CA, US.
2008. CD20 Scientific Platform - Part 1 and Part 2. Invited. 2008 Genentech Advisory Initiative: NHL Regional Academic Meeting. Dallas, TX, US.
2008. Advances in the Treatment of CLL. Invited. American Society of Clinical Oncologists (ASCO). Chicago, IL, US.
2008. Illuminating Possibilities: Making Strides in the Treatment of B-cell Chronic Lymphocytic Leukemia (B-CLL). Invited. Campath Promotional Speakers Bureau Meeting. Mobile, AL, US.
2008. Emerging Treatment Paradigms in the Management of CLL. Invited. CLL Content Development Session 2008. New York, NY, US.
2008. Future Development of Rituxan. Invited. CLL National Advisory Board Meeting. Dallas, TX, US.
2008. Lumilixamab. Invited. Lumiliximab Academic Steering Committee Meeting. La Jolla, CA, US.
2008. Chronic Lymphicytic Leukemia (CLL) Induction: How Hard to Push?. Invited. Duke Debates - Controversies in the Management of Patients with Hematologic Malignancies. Asheville, NC, US.
2008. Clinical Issues and Future Directions in Hematologic Malignancies. Invited. Post-ASH Regional Meeting. San Francisco, CA, US.
2008. Management of CLL and CML. Invited. 4th Annual Cancer Treatment Options. Newport Beach, CA, US.
2008. What's New in the Management of Chronic Lymphocytic Leukemia. Invited. Current Trends in Leukemia, Lymphoma, and Myeloma. Houston, TX, US.
2008. Chemotherapeutic Options: Has Standard Therapy Changed?. Invited. 4th Annual Clinical Breakthroughs and Challenges in Hematologic Malignancies. Tampa, FL, US.
2007. Combined Cyclophosphamide, Fludarabine, Alemtuzumab, and Rituximab (CFAR), an Active Frontline Regimen for High-Risk Patients with CLL. Invited. American Society of Hematology - 2007 Annual Meeting. Atlanta, GA, US.
2007. Optimizing Campath Use to Improve Outcomes in CLL & Future Directions. Invited. ION PACT Meeting. Tysons Corner, VA, US.
2007. Anti B-cell Therapies. Invited. Medimmune Advisory Board Meeting. Gaithersburg, MD, US.
2007. Combination Strategies for Up-front and Early Relapsed Patients. Invited. Indolent Lymphoma Workshop. Arlington, VA, US.
2007. Combination Strategies for Up-Front and Early Relapsed Patients. Invited. Lymphoma Research Foundation, Indolent Lymphoma Workshop. Washington, DC, US.
2007. New Treatment Modalities: Recognize the Role of Targeted Therapy in the Treatment of CLL. Invited. 1st Annual Milton & Dawn Gilman Leukemia & Lymhoma Symposium. Royal Oak, MI, US.
2007. CLL: New Approaches for High-Risk Patients. Invited. Third Annual Oncology Congress. San Francisco, CA, US.
2007. Review and Discussion of CLL Case Study. Invited. Rituxan Advisory Initiative. Atlanta, GA, US.
2007. B-Cell Malignancies Education Network - Focus on Chronic Lymphocytic Leukemia. Invited. B-Cell Malignancies Education Network - Focus on Chronic Lymphocytic Leukemia. Wichita Falls, TX, US.
2007. Chronic Lymphocytic Leukemia. Invited. Current Trends in Leukemia, Lymphoma & Myeloma Series 2007. Los Angeles, CA, US.
2006. Updates in CLL: Prognostic Markers and Their Implication for Treatment Strategies. Conference. 48th Annual American Society of Hematology. Orlando, FL, US.
2006. Chronic Lymphocytic Leukemia. Invited. Grand Rounds. Boston, MA, US.
2006. Chronic Lymphocytic Leukemia. Invited. CLL Grand Rounds. Cincinnati, OH, US.
2005. Chronic Lymphocytic Leukemia. Invited. II Reunion Hematologia 2005. Las Palmas.
2005. Chronic Lymphocytic Leukemia. Invited. IWCLL Meeting. New York, NY, US.
2005. Title not provided. Invited. Texas Hematology-Oncology Center. Dallas, TX, US.
2005. 2005 Rituxan Consultant Initiative. Invited. 2005 Rituxan Consultant Initiative. Chicago, IL, US.
2005. 2005 Rituxan Consultant Initiative. Invited. 2005 Rituxan Consultant Initiative. New York, NY, US.
2005. Chronic Lymphocytic Leukemia. Invited. CMI-certified PeerView Webcast, US.
2005. Chronic Lymphocytic Leukemia. Invited. CME-certified PeerView Webcast, US.
2005. Meet the Experts on Chronic Lymphocytic Leukemia. Invited. Leukemia / Lymphoma Symposium, Patient Education. San Diego, CA, US.
2005. Patient Education: Meet the Experts on Chronic Lymphocytic Leukemia. Invited. Leukemia / Lymphoma Symposium. San Diego, CA, US.
2005. Current Trends in Leukemia, Lymphoma, and Myeloma. Invited. A Post-ASH Update. New York, NY, US.
2005. Current Trends in Leukemia, Lymphoma, and Myeloma:. Invited. A Post-ASH Update. Kansas City, MO, US.
2004. New Developments in the Treatment of Chronic Lymphocytic Leukemia. Invited. NOCR Lymphoma Key Opinion Leader Meeting. Chicago, IL, US.
2004. Chronic Lymphocytic Leukemia (CLL). Invited. Leukemia 2004 Congress Towards the Cure. Houston, TX, US.
2004. Pediatrics. Invited. Leukemia 2004 Congress Towards The Cure. Houston, TX, US.
2004. New Developments in the Treatment of Chronic Lymphocytic Leukemia. Invited. Grand Rounds. Jonesboro, AR, US.
2004. New Developments in the Treatment of Chronic Lymphocytic Leukemia. Invited. 4th Annual B.C. Community Oncology Meeting. Vancouver, US.
2004. New Treatments for Patients with Chronic Lymphocytic Leukemia. Invited. ASH 2003 Highlights. Philadelphia, PA, US.
2004. Overview of Recently Released Data on Monoclonal Antibody Therapy for B-Cell Malignancies. Invited. CME-Roundtable Dinner Meeting. Oklahoma City, OK, US.
2004. Chronic Lymphocytic Leukemia. Invited. Current Trends in Leukemia, Lymphoma and Myeloma. Dallas, TX, US.
2003. Cytogenetics in CLL. Invited. Advanced Leukemia Practitioner Journal Club. Houston, TX, US.
2003. Variant Lymphoid Leukemias. Invited. Advanced Leukemia Practitioner Journal Club. Houston, TX, US.
2003. Treatment of Chronic Lymphocytic Leukemia. Invited. Genentech CME Dinner Program. Visalia, CA, Bakersfield, CA, Fresno CA and Thousand Oaks, CA, 9/2003, US.
2003. Monoclonal Antibodies and Their Use in the Treatment of Hematologic Malignancies. Invited. CME-Roundtable Dinner Meeting. Orlando, FL, US.
2003. The Evolution of IL-2R Targeted Therapy for Hematologic Malignancie. Invited. 2003 Pan-Pacific Lymphoma Conference, CME-certified satellite symposium. Mauna Lani, HI, US.
2003. Treatment of CLL. Invited. Lymphoma Symposium, Aultman Institute. Cleveland, OH, US.
2003. Rituximab-based regimens in CLL. Invited. Current Trends in Leukemia, Lymphoma & Myeloma. San Francisco, CA, US.
2003. Monoclonal Antibodies and Their Use in the Treatment of Hematologic Malignancies. Invited. Hem/Onc Physicians Meeting. San Diego, CA, US.
2003. Treatment of CLL. Invited. Grand Rounds, Mamie McFadden Ward Cancer Center. Beaumont, TX, US.
2003. A potential new therapy for CLL. Invited. HealthStream Web Event Teleconference. Nashville, TN, US.
2003. Rituximab in treatment of CLL. Invited. Rituxan Community Advisory Board Meeting. Berkley, CA, US.
2002. Rituximab in Management of CLL. Invited. Genentech/IDEC Round Table Discussion – CLL. Tampa and Orlando, FL, US.
2002. Current Advances in Treatment of CLL. Invited. Clinical Advances in Leukemia and Lymphoma. Santa Ana Pueblo, NM, US.
2001. Gene therapy and future immunotherapies for CLL. Invited. Clinical Advances in Chronic Lymphocytic Leukemia Conference. Las Vegas, NV, US.

International Presentations

2024. What Clinicians Want to Know: Addressing Current Questions and Controversies in the Management of Chronic Lymphocytic Leukemia- What Clinicians Want to Know. Invited. ASH 2024. San Diego, US.
2024. CLL. Invited. AbbVie Global CLL Advisory Council Meeting at ASH. San Diego, US.
2024. Is Continuous Therapy the Best Option for High-Risk Patients. Invited. Twelfth Annual Meeting of the Society of Hematologic Oncology. Houston, US.
2024. Characteristics Associated With Response to Lisocabtagene Maraleucel (liso-cel) in Patients With R/R CLL/SLL: Exploratory Analyses From the Phase 1/2 TRANSCEND CLL 004 Study. Invited. Twelfth Annual Meeting of the Society of Hematologic Oncology. Houston, US.
2024. Is Continuous Therapy the Best Option for High-Risk Patients. Invited. Twelfth Annual Meeting of the Society of Hematologic Oncology. Houston, US.
2024. Outcomes in High-Risk Subgroups After Fixed-Duration Ibrutinib + Venetoclax for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Up to 5.5 Years of Follow-Up in the Phase 2 CAPTIVATE Study. Poster. 12th Annual Meeting of the Society of Hematologic Oncology. Houston, US.
2024. Outcomes in High-Risk Subgroups After Fixed-Duration Ibrutinib + Venetoclax for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Up to 5.5 Years of Follow-Up in the Phase 2 CAPTIVATE Study. Poster. 12th Annual SOHO Meeting. Houston, US.
2024. Oral Poster -Outcomes in high-risk subgroups after fixed-duration ibrutinib + venetoclax for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): Up to 5.5 years of follow-up in the phase 2 CAPTIVATE study. Invited. ASCO 2024. Chicago, US.
2024. Novel Treatments on the Horizon for CLL. Invited. Tel Aviv Universtiy. TelAviv, IL.
2024. Optimizing first-line treatment outcomes for patients with CLL. Invited. SOHO Isreal Meeting & International Davidoff Conference, IL.
2024. Defined Duration vs MDR Driven Time-limited Therapy - Webcast. Invited. EHA. Vienna, AT.
2024. What roll will non-covalent BTK inhibitors play? - Webcast. Conference. EHA. Vienna, AT.
2023. Poster - P637: TIME-LIMITED TREATMENT WITH ACALABRUTINIB PLUS OBINUTUZUMAB IN TREATMENT-NAÏVE CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS: EARLY RESULTS OF AN ONGOING PHASE 2 TRIAL. Conference. EHA. Frankfurt, US.
2023. Poster - P617: FIXED-DURATION (FD) IBRUTINIB + VENETOCLAX FOR FIRST-LINE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)/SMALL LYMPHOCYTIC LYMPHOMA (SLL): 4-Y FOLLOW-UP FROM FD COHORT OF PHASE 2 CAPTIVATE STUDY. Conference. EHA. Frankfurt, US.
2023. Poster- P377: A PHASE II TRIAL OF MINI-HYPER-CVD WITH VENETOCLAX FOR PATIENTS WITH RELAPSED/REFRACTORY (R/R) PHILADELPHIA CHROMOSOME (PH)-NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL). Conference. EHA. Frankfurt, US.
2023. S146: GENOMIC EVOLUTION AND RESISTANCE TO PIRTOBRUTINIB IN COVALENT BTK-INHIBITOR (CBTKI) PRE-TREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PATIENTS: RESULTS FROM THE PHASE I/II BRUIN STUDY. Conference. S146: GENOMIC EVOLUTION AND RESISTANCE TO PIRTOBRUTINIB IN COVALENT BTK-INHIBITOR (CBTKI) PRE-TREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PATIENTS: RESULTS FROM THE PHASE I/II BRUIN STUDY. FrankFurt, US.
2023. Evolving Concepts in CLL- Decisions at Diagnosis: Incorporating Disease Factors and Biomarkers. Conference. AbbVie. Frankfurt, DE.
2023. B-Cell Tumor Board: Rendering Real World Personalized Treatment Plans in CLL/SLL and MCL Through the Lens of Emerging BTKi Evidence. Invited. Physicians' Education Resource (PER). Chicago, US.
2023. Oral Poster - Outcomes in high-risk subgroups after fixed-duration ibrutinib + venetoclax for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): Up to 5.5 years of follow-up in the phase 2 CAPTIVATE study. Conference. ASCO. Chicago, US.
2023. Defying Odds with Innovation in CLL: Perspectives on Personalized Care, Multi-Agent Platforms,and Sequential Targeted & Cellular Strategies. Invited. PeerView Institute. Chicago, US.
2023. Chronic Lymphoid Leukemia Frontline Treatment. Conference. Hikma Cancer Network: 5th Annual MENA Cancer Forum. Istanbul, TR.
2023. CLL Relapsed/Refractroy & Novel Agents. Conference. Hikma Cancer Network: 5th Annual MENA Cancer Forum. Istanbul, TR.
2023. Frontline Therapies. Invited. SOHO 23 Turkiye. Istanbul, TR.
2023. Management of Relapsed/Refractory Disease: Novel Agents. Conference. SOHO 23 Turkiye. Istanbul, TR.
2023. BTK Inhibitors in CLL: Monotherapy Trials. Invited. DAVA Oncology. Whistler, CA.
2022. MRD as an endpoint?. Invited. German CLL Study Group. Cologne, DE.
2022. Program Director - Applications of Individualized Treatment Strategies for CLL/SLL Symposium. Invited. Clinical Education Alliance. Chicago, US.
2022. Chronic Lymphocytic Leukemia (CLL) Steering Committee. Invited. Abbvie. Chicago, US.
2022. Fixed-duration (FD) Ibrutinib + venetoclax for first-line treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma: 3-year follow-up from the FD cohort of the phase 2 CAPTIVATE study. Invited. PCYC. Chicago, US.
2021. Chair and Moderator - Prognostic markers session. Invited. German CLL Study Group, US.
2019. "The role of CAR-T cells in relapsed-refractory adult ALL and CLL". Invited. AORN Santobono-Paulislipon. Naples, IT.
2018. Updates on Hematology. Invited. AMGEN. Bogota, CO.
2018. Bringing future today: Venetoclax in the management of the 1st relapse setting in CLL. Invited. 29th Pan-Hellenic Congress of Hematology. Thessaloniki, GR.
2018. Combining treatment modalities: useful or superfluous?. Conference. ERIC International Meeting. Barcelona, ES.
2018. Is minimal residual disease as significant in chronic leukemias as it is in acute leukemias?. Invited. Dubrovnik Program, HR.
2018. Venetoclax + ibrutinib. Invited. Annual Canadian CLL Meeting. Winnipeg, CA.
2018. Treatment for Relapsed CLL after CIT. Conference. ASCO. Chicago, US.
2018. Sequencing of New Therapies in CLL. Conference. International Ultmann Chicago Lymphoma Symposium. Chicago, US.
2018. BCL-2 inhibitors in CLL. Conference. International Symosium on CLL. Venice, IT.
2018. Choice of First-Line Therapy for CLL: How to Select and What Are the Prioritized Objectives?. Conference. 22nd Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas and Myeloma. Hollywood, US.
2017. ABT199 during the Chronic Lymphocytic Leukemia. Conference. International Association for Comparative Research on Leukemia and Related Diseases Symposium (IACRLRD). Houston, US.
2017. Assessing Key Factors when Choosing Initial Therapy for Patients with Chronic Lymphocytic Leukemia. Conference. International Association for Comparative Research on Leukemia and Related Diseases Symposium (IACRLRD). Houston, US.
2017. CLL Treatment Goals. Invited. Lebanese Society of Hematology and Blood Transfusion. Beirut, LB.
2017. Today's Cancer Treatment: How Individualized Can It Be?. Conference. Cancer Crosslinks 2017. Oslo, NO.
2016. State-of-the-Art in Frontline Treatment of Patients with Chronic Lymphocytic Leukemia. Invited. European Congress on Hematology: Focus on Lymphoid Malignancies. Paris, FR.

Formal Peers

2024. Addressing Current Questions and Controversies in the Management of Chronic Lymphocytic Leukemia – What Clinicians Want to Know. San Diego, CA, US.
2024. Chronic Lymphocytic Leukemia, US.
2024. Opportunities for Advances in CLL. Houston, TX, US.
2024. Exceeding Expectations in CLL: Workshops on Targeted Standards, Sequential Options, and Emerging Therapeutics for Team-Based Care. Houston, TX, US.
2024. Continuing Education on CLL, US.
2024. Fixed-Duration: A Patient-Captivating Standard of Care in CLL. Web-Based Activity on CLL, US.
2024. Future therapies including CAR-T therapies/Lead Meet the Expert. Vienna, AT.
2024. Chronic Leukemia. Visiting. UTMDACC. Houston, TX, US.
2023. 2023 Hematology Highlights: A Post ASH Review. Invited. The University of Nebraska Medical Center. Omaha, NE, US.
2017. CD20 Targeting with Rituximab and Newer Approaches. Invited. UT Graduate School of Biomedical Sciences. Houston, TN, US.
2016. Developments in the Management of Chronic Lymphocytic Leukemia. Invited. Medical College of Wisconsin. Milwaukee, WI, US.
2016. Navigating the Therapeutic Options in Chronic Lymphocytic Leukemia. Invited. Emory University. Atlanta, GA, US.
2016. Update of Management for CLL. Invited. John Theurer Cancer Center. Hackensack, NJ, US.
2012. New Antibodies for the Treatment of CLL and Lymphoma. Invited. Department of Haematology in Rigshospitalet. Stockholm, SE.
2011. Opportunities for Advancing Treatments for Patients with CLL. Visiting. Memorial Sloan-Kettering Cancer Center. New York City, NY, US.
2009. Treatment for Patients with Chronic Lymphocytic Leukemia (CLL). Visiting. Michael E. Debakey Veterans Affairs Medical Center. Houston, TX, US.
2009. 2009 Hematology Highlights: A Post ASH Review - CLL. Invited. The University of Nebraska Medical Center. Omaha, NE, US.
2008. Clinical Research in CLL: Making New Treatments Available to Patients in Houston. Visiting. The Leukemia & Lymphoma Society. Houston, TX, US.
2007. New Treatment Modalities: Recognize the Role of Targeted Therapy in the Treatment of CLL. Invited. William Beaumont Hospital, Beaumont Cancer Center. Royal Oak, MI, US.
2007. Improving Outcomes in All Stages of CLL - Interpreting Recept Research. Invited. Jewish General Hospital. Quebec City, Quebec, CA.
2007. Future Directions in the Management of CLL. Invited. Windsor Regional Cancer Centre. Windsor, CA.
2007. Management of Resistant CLL. Invited. Princess Margaret Hospital. Toronto, CA.
2007. Improving Outcomes in All Stages of CLL - Interpreting Recent Research. Invited. Sunnybrook Health Sciences Centre. London, CA.
2007. Improving Outcomes in All Stages of CLL - Interpreting Recent Research. Invited. Lakeridge Oshawa Hospital. Hamilton, CA.
2007. Improving Outcomes in All Stages of CLL - Interpreting Recent Research. Invited. London Health Sciences Centre. Ontario, CA.
2007. Use of Rituximab in CLL, both as a single agent and in combination. Invited. Mabthera Brazil. Sao Paulo, BR.
2007. CLL and Hairy Cell Leukemia. Invited. Baylor College of Medicine. Houston, TX, US.
2006. Chronic Lymphocytic Leukemia. Invited. Cancer Care Manitoba. Winnipeg, CA.
2006. CLL. Invited. Cancer Care Manitoba. Winnipeg, CA.
2006. Grand Rounds. Invited. Boston University Medical Center. Boston, MA, US.
2006. Grand Rounds. Invited. University of Cincinnati Medical Center. Cincinnati, OH, US.
2005. CLL and Gene Therapy. Invited. Peter MacCallum. Melbourne, AU.
2005. CME Certified PeerView Webcast. Invited. University of Florida, FL, US.
2005. Patient Education: Meet the Experts on Chronic Lymphocytic Leukemia. Invited. UCSD. San Diego, CA, US.
2003. Treatment of CLL. Invited. (SCOA). Columbia, SC, US.

Less

Grant & Contract Support

Date:	2023 - 2025
Title:	2023-0106 First-in-Human Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of the BTK Degrader, ABBV-101, in Participants with B-cell Malignancies
Funding Source:	AbbVie
Role:	PI

Date:	2023 - 2026
Title:	NO TITLE PROVIDED
Funding Source:	Pending
Role:	Collaborator
ID:	FP00017140

Date:	2023 - Present
Title:	2022-0055 A PHASE IB OPEN-LABEL, MULTICENTER STUDY EVALUATING THE SAFETY, EFFICACY, AND PHARMACOKINETICS OF MOSUNETUZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA
Funding Source:	Genentech Inc
Role:	PI

Date:	2019 - 2024
Title:	2019-0565: A Randomized Phase II Study of Acalabrutinib (ACA) + Venetoclax (VEN) +/- Early Obinutuzumab (OBIN) for Patients with Chronic Lymphocytic Leukemia (CLL)
Funding Source:	AstraZeneca
Role:	PI

Date:	2019 - 2024
Title:	2019-0565: A Randomized Phase II Study of Acalabrutinib (ACA) + Venetoclax (VEN) +/- Early Obinutuzumab (OBIN) for Patients with Chronic Lymphocytic Leukemia (CLL)
Funding Source:	Genentech
Role:	PI

Date:	2018 - 2025
Title:	2018-0850 A Phase 1/2 Study of Oral LOXO-305 in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Non-Hodgkin's Lymphoma (NHL)
Funding Source:	LoxoOncology
Role:	Principal Investigator-MDACC

Date:	2018 - 2025
Title:	2018-0316: A phase I Combination Study of CYC065 and Venetoclax for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
Funding Source:	Cyclacel
Role:	PI
ID:	Pending

Date:	2018 - 2019
Title:	2015-0651 A Phase 1 does-ranging study to investigate the safety, tolerability, and pharmacokinetics of MRG-106 following local intratumoral, subcutaneous injection, and intravenous Administration in Subjects with Various Lymphomas and Leukemias
Funding Source:	MiRagen, Inc
Role:	PI
ID:	00006439

Date:	2018 - 2024
Title:	2017-0889: A Phase 1b-2 Study of the ROR1-Targeting Monoclonal Antibody, Cirmtuzumab (UC-961), and the Bruton Tyrosine Kinase Inhibitor, Ibrutinib, in Patients with B-Cell Lymphoid Malignancies
Funding Source:	Oncternal Therapeutics, Inc
Role:	PI
ID:	CIRM0001/MDACC55474

Date:	2018 - 2024
Title:	2017-0751: An Open-Label, Phase 1 Safety and Phase 2 Randomized Study of JCAR017 in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Funding Source:	Juno Therapeutics, Inc
Role:	PI
ID:	17004-JCAR17/MDACC55252

Date:	2017 - 2019
Title:	2016-0341 A Phase 1 Safety Study of Adoptive Cellular Therapy Using Autologous T Cells Transduced with Lentivirus to Express a CD33 Specific Chimeric Antigen Receptor in Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia
Funding Source:	Ziopharm, Inc
Role:	Principal Investigator-MDACC
ID:	CD-33/MDACC54419

Date:	2017 - 2019
Title:	2017-0158 A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study of the Noncovalent, Reversible Bruton?s Tyrosine Kinase Inhibitor, SNS-062, in Patients With B-Lymphoid Malignancies
Funding Source:	Sunesis
Role:	PI
ID:	062HEM102/MDACC55252

Date:	2017 - 2024
Title:	2016-0875: Phase II Study of the Combination of Ibrutinib Plus Venetoclax in Subjects with Treatment-Naive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Funding Source:	Pharmacyclics, Inc
Role:	PI
ID:	PCYC-1142-CA/MDACC005459

Date:	2017 - 2021
Title:	2016-0991: A Phase 1 Multidose Study To Evaluate the Safety and Tolerability of Xmab 13676 in Patients with Cd20-Expressing Hematologic Malignancies
Funding Source:	Xencor
Role:	PI
ID:	XmAb1367601/MDACC54273

Date:	2016 - 2018
Title:	2015-0416 A Phase 1/2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Subjects with Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r ALL)
Funding Source:	Kite Pharma, Inc
Role:	PI
ID:	KTE-C19-103/MDACC51552

Date:	2015 - 2022
Title:	2015-0416: A Phase 1/2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Subjects with Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r ALL)
Funding Source:	Kite Pharma
Role:	PI
ID:	CS2018-00051552-AM1-RP

Date:	2015 - 2018
Title:	2014-0601: A Phase 2 Study of the Safety & Anti-tumor Activity of the Oral Selective Inhibitor of Nuclear Export Selinexor in Patients with Refractory and/or Relapsed Richter's Transformation
Funding Source:	Karypharm
Role:	PI
ID:	12843

Date:	2014 - 2019
Title:	2014-0405: A Phase 2 Open-Label Study of the Efficacy & Safety of ABT-199 (GDC-0199) in CLL Subjects w/ Relapse or Refractory to B-Cell Receptor Signaling Pathway Inhibitor Therapy
Funding Source:	AbbVie
Role:	PI
ID:	M14-032/MDACC39301

Date:	2014 - 2019
Title:	2013-0486: A Phase IB Multicenter Dose-Finding and Safety Study of GDC-0199 and Obinutuzumab in Patients with Relapsed or Refractory or Previously Untreated Chronic Lymphocytic Leukemia
Funding Source:	Genentech, Inc
Role:	PI
ID:	GP28331/MDACC38644

Date:	2014 - 2019
Title:	2014-0419 A Multicenter, Open-label, Phase 1 Pilot Study of ACP-196 in Combination with ACP-319 in Subjects with Relapsed/Refractory Chronic Lymphocytic Leukemia
Funding Source:	Acerta Pharma, LLC
Role:	PI
ID:	ACE-CL-002/MDACC39286

Date:	2014 - 2015
Title:	Creating Novel Translation Inhibitors to Target Pro-survival Oncoproteins
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Co-I
ID:	RP130660

Date:	2014 - 2017
Title:	2012-0912: A Phase I Dose-Escalation and Pharmacokinetic Study of TG02 Citrate in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
Funding Source:	Tragara
Role:	PI
ID:	7837

Date:	2014 - 2019
Title:	2013-0907 A Phase 1, Multicenter, Open-label, and Dose-escalation Study of ACP-196 in Subjects with Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia
Funding Source:	Acerta Pharma, LLC
Role:	PI
ID:	ACE-CL001/MDACC38195

Date:	2013 - 2018
Title:	2013-0315: A Phase 2 Open-Label Study of the Efficacy of ABT-199 (GDC-0199) in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia Harboring the 17p Deletion
Funding Source:	AbbVie
Role:	PI
ID:	M13-982/MDACC37869

Date:	2013 - 2017
Title:	SCOR: Next-Generation T-Cell Leukemia Trial Targeting ROR1 on CLL
Funding Source:	Leukemia and Lymphoma Society
Role:	Project Leader
ID:	01

Date:	2013 - 2016
Title:	Attacking the specific vulnerability of LKB1-mutant NSCLC to energy depletion using an ATP mimetic
Funding Source:	V Foundation for Cancer Research
Role:	Co-I
ID:	01

Date:	2013 - 2017
Title:	2012-0626 A Phase 1b, Open Label Study to Evaluate the Safety and Efficacy of TRU-016 in Combination with Rituximab or in Combination with Obinutuzumab in Patients with Chronic Lymphocytic Leukemia
Funding Source:	Emergent BioSolutions, Inc
Role:	PI
ID:	0000733

Date:	2013 - 2017
Title:	LAB03-0893 Cellular Therapy for CLL Utilizing Chimeric Antigen Receptors (CARs)
Funding Source:	CLL Global Research Foundation
Role:	PI
ID:	01

Date:	2012 - 2019
Title:	2012-0411 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of GS-1101 (CAL-101) in Combination with Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia
Funding Source:	Gilead Sciences, Inc
Role:	PI
ID:	US-312-0115/MDACC40192

Date:	2012 - 2018
Title:	Chronic Lymphocytic Leukemia Research Consortium Core D
Funding Source:	NIH/NCI
Role:	Core Leader
ID:	5 P01 CA081534-16 Core D

Date:	2012 - 2017
Title:	Chronic Lymphocytic Leukemia Research Consortium Core D multi
Funding Source:	NIH/NCI
Role:	Core Leader
ID:	5 P01 CA081534-13 Core D multi

Date:	2012 - 2018
Title:	2012-0171L A Phase 3, Double-Blind Extension Study Evaluating the Efficacy and Safety of Two Different Dose Levels of Single-Agent GS-1101 (CAL-101) as Therapy for Patients with Previously Treated Chronic Lymphocytic Leukemia
Funding Source:	Gilead Sciences, Inc
Role:	PI
ID:	US-312-0117/MDACC40194

Date:	2012 - 2018
Title:	2012-0707 A Randomized, Multicenter, Open-label, Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib versus Ofatumumab in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Funding Source:	Pharmacyclics, Inc
Role:	PI
ID:	PCYC-1112-CA/MDACC37082

Date:	2012 - 2016
Title:	Sapacitabine therapy to create synthetic lethality in DNA repair-deficient CLL
Funding Source:	NIH/NCI
Role:	PI
ID:	5 R01 CA163802-02

Date:	2012 - 2019
Title:	2011-0142L A Long-Term Safety Study of Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 in B cell Lymphoma and Chronic Lymphocytic Leukemia
Funding Source:	Pharmacyclics, Inc
Role:	PI
ID:	PCYC1112/MDACC00969508

Date:	2012 - 2021
Title:	2011-0164: A Phase 1 Study Evaluating the Safety, Pharmacokinetics and Preliminary Efficacy of ABT-199 in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia
Funding Source:	Abbott
Role:	PI
ID:	M12-175/MDACC34768

Date:	2012 - 2018
Title:	2011-0612 An Extention Study to Investigate the Safety and Durability of Clinical Activity of Idelalisib in Subjects with Hematologic Malignancies
Funding Source:	Gilead Sciences, Inc
Role:	PI
ID:	CAL 101-99/MDACC969261

Date:	2011 - 2017
Title:	2010-0516: A Phase II Clinical Trial of Sapacitabine, Cyclophosphamide, and Rituximab (SCR) for Relapsed Patients with Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma (CLL/SLL) and Deletion 11q22-23 by FISH
Funding Source:	Cyclacel
Role:	PI
ID:	MDACC34318

Date:	2010 - 2020
Title:	2010-0241: Ofatumumab Early Treatment for High-Risk Treatment-Naive, Early Stage (0-II) Patients with CLL
Funding Source:	GlaxoSmithKline
Role:	PI
ID:	COMB157BUS14T/OFT113592/Ofatumumab/MDACC32628

Date:	2010 - 2016
Title:	2010-0123: A Phase II Trial of Eltrombopag for Patients with Chronic Lymphocytic Leukemia (CLL) and Thrombocytopenia
Funding Source:	GlaxoSmithKline
Role:	PI
ID:	ELT113559/MDACC32388

Title:	2018-0302 A phase I/Ib pilot study of Combined Trabectedin and Venetoclax in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Resistant or Intolerant to a BTK inhibitor
Funding Source:	MDACC/Janssen
Role:	Co-PI

Title:	IL15-Secreting Armored CAR-NK cells Targeting CD19+ Cancers
Funding Source:	NATIONAL CANCER INSTITUTE
Role:	Collaborator
ID:	Proposal: FP00005072

CV information above last modified April 17, 2025

William G. Wierda, M.D., Ph.D.

About Dr. Wierda

In the News

Richter transformation: What chronic lymphocytic leukemia (CLL) patients should know

Leukemia specialist: Identifying new treatments is the most gratifying part of my job

Patient care

Present Title & Affiliation

Primary Appointment

Dual/Joint/Adjunct Appointment

Research Interests

Clinical Interests

Education & Training

Degree-Granting Education

Postgraduate Training

Experience & Service

Academic Appointments

Administrative Appointments/Responsibilities

Other Appointments/Responsibilities

Institutional Committee Activities

Honors & Awards

Professional Memberships

Selected Publications

Peer-Reviewed Articles

Invited Articles

Other Articles

Editorials

Abstracts

Book Chapters

Selected Presentations & Talks

Local Presentations

Regional Presentations

National Presentations

International Presentations

Formal Peers

Grant & Contract Support

Patient Reviews

Related Links

Leukemia Center

Leukemia Department

Help #EndCancer

William G. Wierda, M.D., Ph.D.

About Dr. Wierda

In the News

Richter transformation: What chronic lymphocytic leukemia (CLL) patients should know

Leukemia specialist: Identifying new treatments is the most gratifying part of my job

Patient care

Present Title & Affiliation

Primary Appointment

Dual/Joint/Adjunct Appointment

Research Interests

Clinical Interests

Education & Training

Degree-Granting Education

Postgraduate Training

Experience & Service

Academic Appointments

Administrative Appointments/Responsibilities

Other Appointments/Responsibilities

Institutional Committee Activities

Honors & Awards

Professional Memberships

Selected Publications

Peer-Reviewed Articles

Invited Articles

Other Articles

Editorials

Abstracts

Book Chapters

Selected Presentations & Talks

Local Presentations

Regional Presentations

National Presentations

International Presentations

Formal Peers

Grant & Contract Support

Patient Reviews

Request an Appointment

Related Links

Leukemia Center

Leukemia Department

Clinical Trials

Help #EndCancer

Give Now

Donate Blood

Volunteer